<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="pmc-domain-id">2403</journal-id><journal-id journal-id-type="pmc-domain">jimmres</journal-id><journal-id journal-id-type="publisher-id">jir</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8166496</article-id><article-id pub-id-type="pmcid-ver">PMC8166496.1</article-id><article-id pub-id-type="pmcaid">8166496</article-id><article-id pub-id-type="pmcaiid">8166496</article-id><article-id pub-id-type="pmid">34124272</article-id><article-id pub-id-type="doi">10.1155/2021/9912188</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Toll-Like Receptor-Based Strategies for Cancer Immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3117-6370</contrib-id><name name-style="western"><surname>Pahlavanneshan</surname><given-names initials="S">Saghar</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2338-9840</contrib-id><name name-style="western"><surname>Sayadmanesh</surname><given-names initials="A">Ali</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0689-1281</contrib-id><name name-style="western"><surname>Ebrahimiyan</surname><given-names initials="H">Hamidreza</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2512-7641</contrib-id><name name-style="western"><surname>Basiri</surname><given-names initials="M">Mohsen</given-names></name><email>mohsenbasiri@gmail.com</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran</aff><aff id="I2">
<sup>2</sup>Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran</aff><author-notes><fn fn-type="other"><p>Academic Editor: Tomasz M. Karpi ski</p></fn></author-notes><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>22</day><month>5</month><year>2021</year></pub-date><volume>2021</volume><issue-id pub-id-type="pmc-issue-id">372844</issue-id><elocation-id>9912188</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2021</year></date><date date-type="rev-recd"><day>28</day><month>4</month><year>2021</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>05</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>11</day><month>06</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-01 12:25:12.140"><day>01</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2021 Saghar Pahlavanneshan et al.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JIR2021-9912188.pdf"/><abstract><p>Toll-like receptors (TLRs) are expressed and play multiple functional roles in a variety of immune cell types involved in tumor immunity. There are plenty of data on the pharmacological targeting of TLR signaling using agonist molecules that boost the antitumor immune response. A recent body of research has also demonstrated promising strategies for improving the cell-based immunotherapy methods by inducing TLR signaling. These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. Altogether, reviewed publications suggest that TLRs make a potential target for the immunotherapy of cancer.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Cancer immunotherapies have been of great promise for the treatment of different types of cancer. Checkpoint inhibitors such as anti-PD-1/PDL-1 and anti-CTLA4 antibodies that can treat solid cancers through activation of an antitumor immune response are now approved by regulatory organizations in Europe and the US [<xref rid="B1" ref-type="bibr">1</xref>]. Cell-based immunotherapies such as chimeric antigen receptor (CAR) T cells have also shown to be strikingly effective in treating refractory or relapsed hematopoietic malignancies [<xref rid="B2" ref-type="bibr">2</xref>]. These successful experiences showed that triggering an efficient antitumor immune response could be applied as an effective therapy for cancer. To this end, exploiting relevant immunostimulatory mechanisms is of great importance for the development of new potent immunotherapy strategies. Toll-like receptors (TLRs) are a class of molecules that play such immunostimulatory roles in many immune cells involved in cancer immunity.</p><p>TLRs are a well-known family of pattern recognition receptors that recognize conserved structures in pathogens. The extracellular TLR groups (TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) are expressed on the plasma membrane while intracellular TLR groups (TLR3, TLR7, TLR8, and TLR9) are expressed in the endosome and endoplasmic reticulum, whereas TLR4 is found both on the plasma membrane and in the intracellular compartments. These molecules detect infection-derived ligands through their extracellular/luminar domain known as leucine-rich repeats (LRRs) and signal through their cytosolic conserved region known as toll-like/interleukin-1 receptor (TIR) homology domain to trigger the downstream signaling adaptor proteins such as myeloid differentiation primary response gene 88 (MyD88) [<xref rid="B3" ref-type="bibr">3</xref>].</p><p>TLRs are expressed on a variety of cells, including innate immune system cells such as macrophages, neutrophils, dendritic cells (DCs), natural killer (NK) cells, and mast cells, as well as the adaptive immune system (T and B lymphocytes), stromal cells, and different types of tumor cells [<xref rid="B4" ref-type="bibr">4</xref>]. The wide expression and functional role of TLRs in the tumor-infiltrating immune cells and the intrinsic role of these cell types in cancer progression or anticancer immune response highlight the potential of TLR as a promising target for cancer immunotherapy. Therefore, pharmacological compounds that can activate TLR molecules have been extensively studied for boosting the immune response against malignant cells. As we discuss in the next sections, this strategy not only activates intrinsic immune cells but also can benefit adoptively transferred immune cells in cell-based immunotherapy settings. Moreover, since TLRs are potent stimulatory molecules in many immune cells, their signaling domains can be applied for engineering synthetic molecules such as CARs for genetic modification of therapeutic immune cells. In this review, we first discuss the role of TLRs in the immune microenvironment of cancer to provide a background on the roles played by TLRs in the cancer microenvironment. Then, we will survey current reports on the application of TLR modulators in cancer immunotherapy and the TLR-based strategies for boosting immune cell therapies of cancer.</p></sec><sec id="sec2"><title>2. TLRs in Cancer Immunity</title><sec id="sec2.1"><title>2.1. Dendritic Cells</title><p>Although the frequency of DCs in the tumor microenvironment is low, they are very important to orchestrate antitumor response in the tumor microenvironment [<xref rid="B5" ref-type="bibr">5</xref>]. It is demonstrated that maturation of murine DCs directed by TLR stimulation primes antigen presentation and is pivotal for induction of T cell cytotoxicity. Signaling via activated TLR3 and TLR7 exerts maturation of DC subpopulations and enhances DC-directed immunogenicity mainly via IL-27-mediated signaling [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Notably, activation of TLR3 on human breast cancer-associated dendritic cells has been shown to increase IFN-<italic toggle="yes">&#955;</italic> production which in turn directed IL-12 release. This IFN-directed phenotype provided a Th1 microenvironment and enhanced cytotoxic T cell activation [<xref rid="B8" ref-type="bibr">8</xref>]. Activation of TLR4 has been shown to enhance DC maturation which promoted anticolorectal cancer T cell response in vitro [<xref rid="B9" ref-type="bibr">9</xref>]. Similarly, stimulation of DCs via TLR-4 activation and tumor antigens significantly increased cytotoxic CD8+IFN<italic toggle="yes">&#947;</italic>+ T cells <italic toggle="yes">in vivo</italic> [<xref rid="B10" ref-type="bibr">10</xref>]. Stimulation of TLR7/8 on dendritic cells isolated from leukemic blasts of AML patients has been shown to promote efficient maturation and subsequently activate autologous cytotoxic T cells in vitro. Furthermore, targeting TLR7/8 was a crucial addition to TLR3, 2, or 4 activations to prime DC maturation and production of IL-12 [<xref rid="B11" ref-type="bibr">11</xref>].</p><p>Moreover, activation of plasmacytoid dendritic cells via TLR7 signaling interestingly resulted in murine melanoma cell killing. TLR7 enabled tumor-associated effector pDCs to educate NK cells, mDCs, as well as activation of CD8+ T cells [<xref rid="B12" ref-type="bibr">12</xref>]. A similar trend was also observed on ALL patients. pDC activation via TLR9 molecules directed IFN production which in turn activated NK cells by engagement of TRAIL and CD69 expression [<xref rid="B13" ref-type="bibr">13</xref>]. This antitumor TLR7 effect was also shown in CNS tumors which increased DC maturation and tumor-specific CD8+ T cells in mice [<xref rid="B14" ref-type="bibr">14</xref>]. Activation of DCs via TLR3 and TLR7/8 activated CD8+ T cell response and improved therapeutic activity of DC-targeted vaccines [<xref rid="B15" ref-type="bibr">15</xref>].</p></sec><sec id="sec2.2"><title>2.2. Macrophages</title><p>Macrophages are important immune cells functioning as tumor-protective subtype M1 or tumor-promoting M2 subtypes. It is well evident that skewing M2 subtypes in the tumor microenvironment to M1 can enhance antitumor properties of M1 macrophages [<xref rid="B16" ref-type="bibr">16</xref>]. Studies demonstrated the role of TLR3 activation to revert M2 phenotype to M1 mainly via recruiting IFN signaling cascade in vitro and in vivo. The latter resulted in the expression of costimulatory molecules such as CD80, CD86, and CD40 as well as immunostimulatory cytokines IL-6, IL-12, and TNF-<italic toggle="yes">&#945;</italic>. Consequently, this resulted in improved antigen uptake by macrophages and become capable of activating T cells which augmented immune control of tumor growth in mice [<xref rid="B17" ref-type="bibr">17</xref>]. A similar result was obtained against Lewis lung carcinoma cancer cells in mice via TLR3 activation as well as TLR4 engagement in sarcoma-bearing mice [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. It has shown that TLR4 may have effects on macrophage migration via NF-<italic toggle="yes">&#954;</italic>B, TNF-<italic toggle="yes">&#945;</italic>, and VEGF expression [<xref rid="B20" ref-type="bibr">20</xref>]. In another study, antitumor crosstalk between macrophages and NK cells via engagement of TLRs was shown ex vivo. This TLR-directed M1 antitumor phenotype was accompanied by the production of immunostimulatory cytokines such as IL-18 from human ovarian tumors and stimulated resting NK cells to produce IFN<italic toggle="yes">&#947;</italic> and Th1-type immune responses [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>Furthermore, it is well documented that myeloid-derived suppressor cell (MDSC) differentiation to either M1 or M2 macrophages is possible in tumor environment which can exert antitumor or protumor effects, respectively [<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>]. TLR7/8 activation has been shown to differentiate MDSCs in the tumor microenvironment towards M1 phenotype and enhance tumor regression in mice. This TLR-directed antitumor activity synergistically decreased oxaliplatin resistance in mice harboring colorectal cancer [<xref rid="B24" ref-type="bibr">24</xref>]. The role of TLR2/6 stimulation on macrophages to derive NK cell activation and T cell cytotoxicity was also reported in several tumors such as pancreatic cancer as well as metastasis mice models [<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. This NF-<italic toggle="yes">&#954;</italic>B-directed signaling increases COX-2 expression on macrophages and monocytes to derive immune surveillance in tumors [<xref rid="B25" ref-type="bibr">25</xref>].</p></sec><sec id="sec2.3"><title>2.3. Tumor Cells</title><p>TLR8-mediated signaling in tumor cells reversed immune suppression in the tumor microenvironment via blocking cAMP production. This helped overcome na&#239;ve/effector T cell senescence in the immunosuppressive microenvironment of tumor cells [<xref rid="B27" ref-type="bibr">27</xref>]. Crosstalk between tumor cells and <italic toggle="yes">&#947;&#948;</italic> T cells via TLR2 and TLR7 signaling has been reported. TLR2 and 7 activations directed CD54 expression in pancreatic adenocarcinoma and lung and head and neck carcinomas which significantly directed effector function of T cells in vitro [<xref rid="B28" ref-type="bibr">28</xref>]. TLR7 activation of tumor cell lines such as Hela S3, keratinocytes, and fibroblasts directly promoted tumor cell apoptosis [<xref rid="B29" ref-type="bibr">29</xref>]. Moreover, this antiapoptosis effect TLR7 activation can be directed via infiltrated cytotoxic lymphocytes (CTL), NK, and DCs in the tumor microenvironment. Activation of TLR3-promoted apoptosis of prostate cancer cells via PKC-alpha-dependent signaling in combinational therapy with 5-FU significantly increased apoptosis of human colon cancer cells [<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. The direct antitumor effect of TLR5 activation has been reported in mouse xenografts of human breast cancer cells [<xref rid="B32" ref-type="bibr">32</xref>]. The same autocrine effect of TLR5 activation was also reported on glioma cells via NF-kappaB activation and NO production [<xref rid="B33" ref-type="bibr">33</xref>].</p></sec><sec id="sec2.4"><title>2.4. B Cells</title><p>B cells express a variety of TLRs which can transmit strong activation signals that synergize with B cell receptor signaling [<xref rid="B34" ref-type="bibr">34</xref>]. The role of TLR7, as well as TLR8, on enhancing B cell antibody and cytokine production is well documented. These activated B cells which are similar to CD40-activated B cells showed increased survival and upregulation of B7 costimulatory molecules [<xref rid="B35" ref-type="bibr">35</xref>]. Stimulation of TLR1/2, TLR7, and TLR9 in B cells induces the secretion of a wide range of cytokines and chemokines [<xref rid="B36" ref-type="bibr">36</xref>]. Increased expression of costimulatory molecules, enhanced cytokine production, and more efficient antigen presentation by B cells can consequently result in better activation of the helper T cells [<xref rid="B34" ref-type="bibr">34</xref>]. There are also several reports demonstrating that TLR stimulation promotes effector functions of B cells including proliferation, antibody production, and Ig class switching [<xref rid="B37" ref-type="bibr">37</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>].</p></sec><sec id="sec2.5"><title>2.5. NK Cells</title><p>NK cells are a type of lymphocyte that functions as a first-line defense against tumor cells. It is well documented that almost all TLRs can be expressed on NK cells depending on the NK cell population. Among all, signaling via TLR3, 7, 8, and 9 had been shown as a crucial route in tumor biology. Activation of TLR3 which is highly expressed on human NK cell lines such as NK92, YTC12, and YTS resulted in enhanced cytotoxicity effects on K562 cells. Moreover, targeting TLR3 enabled NK cells to kill head and neck squamous cell carcinoma (HNSCC) by secreting IFN<italic toggle="yes">&#947;</italic> [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>]. Activation of nucleic acid-sensing TLRs such as TLR7, 8, and 9 has been reported to enable the antitumor activity of NK cells. Activation of these TLRs is highly dependent on other cells in the tumor microenvironment. Although the expression of TLR7/8 on NK cells is controversial [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>], some reports showed that stimulation of TLR7/8 expression on NK cells via cytokines released from other cells activates NK cells and promotes their proliferation. Secretion of IFN<italic toggle="yes">&#947;</italic> and IL-12 and other inflammatory cytokines via TLR7/8 stimulation enabled NK cells to kill HNSCC and melanoma B16 tumor cells while TLR9 triggered cytotoxic activity of these cells on melanoma cells [<xref rid="B44" ref-type="bibr">44</xref>&#8211;<xref rid="B46" ref-type="bibr">46</xref>]. It was also reported that activation of NK cells via TLR2 could accelerate the antitumor activity of HER2-targeted monoclonal antibody therapy <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> [<xref rid="B47" ref-type="bibr">47</xref>].</p></sec><sec id="sec2.6"><title>2.6. Effector T Cells</title><p>Certain TLRs are expressed on different types of T cells which can directly modulate T cell function and antitumor activity of these cells. TLR1/2, 5, and 7/8 activation has been reported to stimulate proliferation and cytokine production of memory CD4+ T cells. For instance, increased secretion of IFN<italic toggle="yes">&#947;</italic> and a slight increase in IL6 from freshly isolated <italic toggle="yes">&#947;&#948;</italic> T cells have been reported via TLR2 and TLR3 stimulations. A high concentration of TLR5 ligand increased CD4+ T cell proliferation and IL2 expression [<xref rid="B48" ref-type="bibr">48</xref>]. Activation of several TLRs such as TLR2, 3, and 9 in purified B6 CD4+ T cells can act as a costimulatory signal for TCR activation [<xref rid="B49" ref-type="bibr">49</xref>]. TLR9 activation via NF-<italic toggle="yes">&#954;</italic>B signaling inhibits apoptosis in CD4+ T cells; similarly, signaling via activation of TLR2 stimulated CD8+ T cell survival [<xref rid="B50" ref-type="bibr">50</xref>]. TLR7 and TLR8 activation of CD4+ T cells helped proliferation and enhanced production of IFN<italic toggle="yes">&#947;</italic>, IL-2, and IL-10 [<xref rid="B51" ref-type="bibr">51</xref>]. Moreover, activation of TLR7 induced effector activity of CD8+ T cells via the MyD88 and AKT-mTOR pathway which is strongly dependent on glucose uptake <italic toggle="yes">in vitro</italic> [<xref rid="B52" ref-type="bibr">52</xref>]. Although as mentioned earlier, activation of DCs, NK cells, and Tregs can modulate CD8+ T cell function, it is well documented that different TLRs can directly modulate different properties of CD8+ T cells in the tumor microenvironment. TLR1/2 activation is believed to entail effector activity to CD8+ T cells. Granzyme B, perforin, TNF-<italic toggle="yes">&#945;</italic>, and IFN<italic toggle="yes">&#947;</italic> production is augmented via TLR1/2 activation both in vivo and in vitro. Ligation of TLR1/2 on CTLs could generate antitumor activity against B16 melanoma cells and result in significant tumor reduction [<xref rid="B53" ref-type="bibr">53</xref>]. This enhanced CTL cytotoxicity is suggested to be at least partly via the mTOR pathway. Inhibition of mTOR, Akt, and PKC in T cells hindered cytotoxic activity of CD8 T cells dramatically [<xref rid="B54" ref-type="bibr">54</xref>]. It is reported that TLR3 activation can also modulate effector CD8+ T cell function and increase IFN<italic toggle="yes">&#947;</italic> production as a functional coreceptor [<xref rid="B55" ref-type="bibr">55</xref>]. Moreover, direct activation of CD8+ T cells via engaging TLR3 is reported in an in vitro assay using transgenic OT-1 (CD8+) T cells. This antigen-independent stimulation of CD8+ T cells was followed by robust expansion and increased expression of activation markers in vivo [<xref rid="B56" ref-type="bibr">56</xref>].</p></sec><sec id="sec2.7"><title>2.7. Regulatory T Cells</title><p>It is well documented that specific TLRs can modulate the suppressive activity of murine and human regulatory T cells (Tregs). Activation of TLR4 on Treg improved their survival and enhanced their suppressive activity. Besides, TLR5 activation in a low concentration of ligand increased Foxp3 expression and slightly enhanced suppressive activity of human CD4+CD25+ Treg [<xref rid="B48" ref-type="bibr">48</xref>]. In contrast, TLR8 activation of Tregs via TLR8-MyD88-IRAK4 signaling could significantly revert the suppressive function of these cells in a tumor-bearing mouse model [<xref rid="B57" ref-type="bibr">57</xref>]. The effect of TLR2 activation to promote Treg proliferation was shown in several experiments although its effect on reverting suppressive activity of these cells is controversial [<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>]. For example, TLR2 activation was reported to directly promote proliferation of Tregs <italic toggle="yes">in vivo</italic>; however, it inhibits immunosuppressive activity [<xref rid="B60" ref-type="bibr">60</xref>]. Since the overall effects of most TLR agonists are towards the enhancement of antitumor effects (see next section), one can speculate that TLR-mediated stimulation of Tregs is not a major challenge for TLR-based immunotherapy. However, more precise investigations are required to address the underlying mechanisms that orchestrate immune cell interactions during systemic TLR stimulation.</p></sec></sec><sec id="sec3"><title>3. TLR Agonists for Cancer Immunotherapy</title><p>Given the current knowledge on TLR and their ligands, various types of TLR agonists are developed including natural microbial components or synthetic ones and being used in anticancer therapy. These agents are considered immune-stimulating factors which enhance TLR signaling and activate an innate immune response that results in long-lasting adaptive immunity. The TLR agonists have been used for a variety of clinical applications. These agents could be used as vaccine adjuvants which caused strong TH1 and CTL response [<xref rid="B61" ref-type="bibr">61</xref>]. The MPLA is a TLR agonist that enhances immunity in hepatitis B vaccines [<xref rid="B62" ref-type="bibr">62</xref>]. The CpG ODN is also used in various vaccines such as hepatitis B, hepatitis C, and influenza which unlike complete Freund's adjuvant does not initiate local inflammatory reaction [<xref rid="B63" ref-type="bibr">63</xref>]. Another application of TLR agonist is for the treatment of allergic diseases with TLR agonists that enhance TH1 response, inhibiting TH2 development and related cytokines such as IL-4, IL-5, and IL-10 [<xref rid="B64" ref-type="bibr">64</xref>]. VTX-1463 (a TLR4 agonist) could reduce clinical symptoms in ragweed-allergic patients [<xref rid="B65" ref-type="bibr">65</xref>]. Treatment of infectious diseases is another application of TLR agonists. These molecules could enhance the specific immune response against microbial infections.</p><p>TLR agonists have been extensively studied for the enhancement of the immune response against cancer. These molecules could stimulate cytotoxic lymphocytes, natural killer cells (NK cells), and dendritic cells (DCs) which could be important characteristics in cancer therapy either in monotherapy or combined modal strategies. These agents are also used as vaccine adjuvants in humans to increase the immune response [<xref rid="B66" ref-type="bibr">66</xref>]. Although TLR agonists are generally considered potential anticancer agents, it should be noticed that the efficacy of some TLR antagonists may be dependent on the cancer type and the context of the immune system [<xref rid="B67" ref-type="bibr">67</xref>].</p><p>There are several examples of TLR agonists studied for boosting anticancer immune response. TLR2 agonists Pam3Cys (synthetic triacylated lipoproteins), SMP-105 (cell wall skeleton components), have been used for bladder cancer [<xref rid="B68" ref-type="bibr">68</xref>]. TLR3 stimulator poly I:C (a synthetic analog of viral dsRNA) increased production of type I IFNs and inhibited tumor cell proliferation [<xref rid="B69" ref-type="bibr">69</xref>], and ARNAX (DNA-capped dsRNA modulator, TLR3 agonist) increased CTL and memory cell numbers [<xref rid="B70" ref-type="bibr">70</xref>]. Multiple TLR4 activators have been studied in experimental and clinical trials, including AS04 (FDA-approved for cervical cancer), MPLA (derivative of lipid A, cervical cancer), and GLA-SE (G100-synthetic GLA, lymphoma tumor) [<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>]. CBLB502 (natural flagellin/entolimod) and M-VM3 (Mobilan, a recombinant nonreplicating adenovirus encoding flagellin) are some of the TLR5 agonists which have been studied for head and neck cancer and prostate cancer, respectively [<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>]. Imiquimod (a TLR7 agonist) is used for cervical, vaginal, and vulvar intraepithelial cancers [<xref rid="B75" ref-type="bibr">75</xref>]. Some of the important examples of TLR9 agonists are CpG-7909 (single-stranded CpG ODN, non-Hodgkin's lymphoma, renal cell carcinoma, melanoma, cutaneous T cell lymphoma and glioblastoma, and non-small-cell lung cancer), IMO2055 (CpG ODN-based oligonucleotide, advanced NSCLC), MGN1703 (natural DNA molecule, advanced solid tumors, small cell lung cancer), dSLIM (two single-stranded loops connected with double-stranded stem, metastatic colorectal cancer), SD-101 (follicular lymphoma), KSK-CpG (phosphorothioated CpG ODN, melanoma), ODN M362 (hepatocarcinoma), and CpG-1826 (enhance anticancer effect in glioma xenograft model) [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B76" ref-type="bibr">76</xref>&#8211;<xref rid="B90" ref-type="bibr">90</xref>].</p><p>A list of TLR agonists which are mentioned above is summarized in <xref rid="tab1" ref-type="table">Table 1</xref> (see also <xref ref-type="fig" rid="fig1">Figure 1</xref>). Although there may be more established or candidate TLR agonists under different phases of preclinical and clinical studies, they follow more or less similar biological strategies to induce TLR signaling. Another strategy is to combine TLR agonists with other immunotherapy agents to obtain a synergistic effect. For instance, combining TLR7 and TLR9 agonists (1V270 and SD-101) with anti-PD1 checkpoint inhibitor activated tumor-infiltrated macrophages and induced a potent antitumor immune response, preventing primary tumor growth and metastasis in a mouse model of head and neck cancer [<xref rid="B91" ref-type="bibr">91</xref>]. Similar enhancement in the immune response was obtained by combining the agonists of TLR9 (ODN1826 or MGN1703) with CTLA-4 or PD-1 blockade in a mouse model of poorly immunogenic melanoma [<xref rid="B92" ref-type="bibr">92</xref>]. It is noteworthy that some TLR antagonists including small molecules, interfering RNAs, and antibodies also have been used for cancer therapy. However, the rationale behind the application of these TLR inhibitors is to target protumor TLRs expressed on the malignant cells and not the immune cells. One of the challenges with these antagonists is that they cannot target TLRs specifically on the tumor cells and may cause unfavorable effects on the immune microenvironment of cancer. We do not cover this approach here since it is not considered immunotherapy; thus, it is out of the scope of this review and has been reviewed elsewhere [<xref rid="B93" ref-type="bibr">93</xref>].</p></sec><sec id="sec4"><title>4. TLR-Based Strategies in Immune Cell-Based Therapy of Cancer</title><p>Several types of immune cells including T cells, NK cells, DCs, and macrophages have been used for cancer immunotherapy, as reviewed elsewhere [<xref rid="B116" ref-type="bibr">116</xref>&#8211;<xref rid="B119" ref-type="bibr">119</xref>]. Since TLRs are involved in the regulation of these immune cells, it is plausible that manipulation of TLRs modifies and improves these cell-based immunotherapy methods. To exploit TLR-based regulation for enhancing transferred cell-based immunotherapy, two general strategies are conceivable: first, to utilize TLR or their derivative domains for genetic modification of the immune cells to augment their functionality against the malignant cells; second, to administrate a TLR agonist or antagonist along with the immune cells to provide them with inflammatory and costimulatory signals. In this section, we will discuss current progress in these approaches and possible future opportunities.</p><p>Genetic modification of immune cells provides a valuable means for directing their function towards the tumor cells and arms them with transgenes that confer resistance against the harsh immunosuppressive microenvironment of the tumor. For instance, genetic modification of T cells by CARs enables them to recognize and kill the tumor cells via surface antigens [<xref rid="B120" ref-type="bibr">120</xref>]. CAR molecule is an engineered transmembrane protein that can recognize a specific antigen by its extracellular domain, typically a single-chain fragment variable (scFV), and transmit activation signals through its cytosolic domains [<xref rid="B121" ref-type="bibr">121</xref>]. Signals transmitted by the cytosolic domains play a crucial role in regulating different aspects of cytotoxicity, memory formation, and persistence of CAR T cells [<xref rid="B122" ref-type="bibr">122</xref>]. First-generation CARs harboring only a CD3<italic toggle="yes">&#950;</italic> signaling domain proved inferior to the second-generation CARs which contain an additional signaling domain from a costimulatory receptor such as CD28 (Figures <xref ref-type="fig" rid="fig2">2(a)</xref> and <xref ref-type="fig" rid="fig2">2(b)</xref>) [<xref rid="B123" ref-type="bibr">123</xref>]. Since TLRs provide potent costimulatory signals for T cell activation, their intracellular domains also can be used for the construction of the CAR molecules. Accordingly, a third-generation anti-CD19 CAR containing CD28, CD3<italic toggle="yes">&#950;</italic>, and TLR2 signaling domains (1928zT2) revealed the synergistic effect between TLR2 and CD28 costimulatory signals (<xref ref-type="fig" rid="fig2">Figure 2(c)</xref>) [<xref rid="B124" ref-type="bibr">124</xref>]. A recent study shows that tethering a TLR adaptor molecule, MyD88, along with a CD40 signaling domain to the cytosolic domain of a first-generation CAR construct promotes CAR T cell survival, proliferation, and antitumor activity (<xref ref-type="fig" rid="fig2">Figure 2(d)</xref>) [<xref rid="B125" ref-type="bibr">125</xref>]. The same MyD88-CD40 fusion protein when linked to a rimiducid-binding domain (FKBP12v36) forms an inducible switch molecule that can enhance <italic toggle="yes">in vivo</italic> expansion and persistence of CAR T cells upon systemic administration of the small molecule rimiducid (<xref ref-type="fig" rid="fig2">Figure 2(e)</xref>) [<xref rid="B126" ref-type="bibr">126</xref>]. Previous studies have shown that signaling through different costimulatory domains results in distinct functional characteristics in CAR T cells in terms of memory differentiation, persistence, and toxic side effects [<xref rid="B122" ref-type="bibr">122</xref>, <xref rid="B127" ref-type="bibr">127</xref>], implying that the selection of the costimulatory domain can be applied to fine-tune CAR T cell function. Therefore, the aforementioned TLR-derived costimulatory domains can expand the signaling domain arsenal to further customize CAR architecture and function.</p><p>Besides T cells, TLR signaling components have also been used in the context of other immune cells that can also be genetically engineered by specific variants of CARs. For instance, the aforementioned rimiducid-inducible molecular switch composed of MyD88, CD40, and FKBP12v36 domains (<xref ref-type="fig" rid="fig2">Figure 2(e)</xref>) has been used in NK cells genetically modified with CAR and IL-15, resulting in the robust proliferation and prolonged persistence in vivo [<xref rid="B128" ref-type="bibr">128</xref>]. Another example of the application of TLR-derived domains for genetic engineering of the immune cells comes from CAR-modified macrophages. Macrophages genetically modified to express CAR molecule consisting of an extracellular scFV domain and a cytosolic TIR domain are reported to show antigen-specific cytotoxicity and expansion both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> [<xref rid="B129" ref-type="bibr">129</xref>, <xref rid="B130" ref-type="bibr">130</xref>]. These instances suggest that genetically engineered receptors mimicking TLR stimulation may be used to modify immune cells which naturally express and get stimulated by TLRs.</p><p>As mentioned earlier, agonists of different TLRs can trigger the antitumor response by modulating specific types of endogenous immune cells. The same principle can be applied for upregulating the adoptively transferred immune cells. For instance, poly I:C (a TLR3 ligand) treatment has been shown to synergize with an antiepidermal growth factor receptor variant III (EGFRvIII) CAR T cell therapy in immunocompetent xenograft models of colon and breast cancer [<xref rid="B131" ref-type="bibr">131</xref>]. In this setting, poly I:C mediated its effect through type I IFNs and downregulation of immunosuppressive myeloid-derived suppressor cells (MDSCs). TLR agonists have also been used for ex vivo activation of the immune cells before being transferred for cancer therapy. For example, coculture of NK cells and DCs in the presence of lipopolysaccharide, which is TLR4 agonist, resulted in superior DC maturation with potent antitumor activity when transferred to a mouse colon cancer model [<xref rid="B132" ref-type="bibr">132</xref>]. This approach can be extended to other immune cell therapies and various TLR agonists and antagonists, considering the compelling data on the effect of the TLR modulators on the antitumor effects of T cells [<xref rid="B133" ref-type="bibr">133</xref>], NK cells [<xref rid="B134" ref-type="bibr">134</xref>], DCs [<xref rid="B135" ref-type="bibr">135</xref>], and macrophages [<xref rid="B136" ref-type="bibr">136</xref>].</p></sec><sec id="sec5"><title>5. Recent Clinical Trials on TLR-Based Cancer Immunotherapy</title><p>TLR agonists have been under clinical investigation for years and in several cases showed potential therapeutic efficacy against cancers. The US Food and Drug Administration (FDA) has approved several TLR agonists for cancer treatment, such as BCG (a primarily TLR2/4 agonist) for bladder noninvasive transitional cell carcinoma, AS04 (a TLR4 agonist) for cervical cancer, and imiquimod (a TLR7 agonist) for superficial basal cell carcinoma [<xref rid="B137" ref-type="bibr">137</xref>]. More recent published results on clinical investigation of TLR agonists in cancer (<xref rid="tab2" ref-type="table">Table 2</xref>) showed the benefit of these molecules when combined with another immunotherapy agent. For example, combining peptide or recombinant cancer vaccines with agonists of TLR3, 4, and 9 showed improved immune stimulation and enhanced T cell response in melanoma patients [<xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>]. The addition of TLR8 agonist Motolimod (VTX-2337) improved the cellular antitumor immune response induced by an anti-EGFR antibody (cetuximab) in head and neck squamous cell carcinoma [<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>]. One report described the simultaneous administration of cell-based immunotherapy with a TLR3 agonist, where treatment with peptide-pulsed DCs plus poly-ICLC was tolerated and induced a detectable tumor-specific T cell response in patients with pancreatic cancer [<xref rid="B142" ref-type="bibr">142</xref>]. However, the addition of TLR2 agonist CADI-05 to chemotherapy with cisplatin-paclitaxel did not provide any survival benefit for non-small-cell lung cancer patients in a phase II clinical trial [<xref rid="B143" ref-type="bibr">143</xref>]. Another study that combined paclitaxel chemotherapy with a TLR7 agonist (imiquimod) showed a short-lived improvement in disease regression [<xref rid="B144" ref-type="bibr">144</xref>].</p><p>Trends of the ongoing clinical trials also suggest that combinatorial strategies are being pursued in the field of TLR agonists. A summary of ongoing clinical trials started between 2019 and April 2021 is provided in <xref rid="tab3" ref-type="table">Table 3</xref>. Clinical trials started before this period are reviewed elsewhere [<xref rid="B137" ref-type="bibr">137</xref>]. Most of these recently started studies are on a combination of TLR inhibitors with another immunotherapy agent including PD-1 blockers, CTLA-4 blockers, and agonistic anti-OX40 antibodies. This is in line with recent preclinical findings that also suggest that this kind of combination may produce a synergistic effect to evoke a more effective immune response [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>].</p></sec><sec id="sec6"><title>6. Conclusion</title><p>TLRs are present on multiple immune cells within the tumor microenvironment. Given the important role of these receptors on the regulation of immune response, they are considered to be promising targets for modulation of the immune system towards a potent antitumor response. Recent data on the application of TLR agonists in experimental and clinical settings demonstrate the potential of this strategy for cancer treatment. Although current studies have shown the proof of concept for the application of TLR-targeted drugs for cancer treatment, given the variations in tumor immunophenotypes, it is likely that cancer type and microenvironment condition among other factors may affect the clinical outcome of TLR-targeting immunotherapies. These differences need to be addressed especially when preclinical animal experiments are conducted. More recent data suggest that combining TLR antagonists with other immunotherapy approaches, such as checkpoint inhibitors and cell-based immunotherapy, could boost the efficacy of immunotherapy regimens [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B131" ref-type="bibr">131</xref>]. The trend of recent clinical trials also suggests that combinatorial therapy containing a TLR agonist as a booster for immune response is considered as a more promising approach by the investigators (Tables <xref rid="tab2" ref-type="table">2</xref> and <xref rid="tab3" ref-type="table">3</xref>). As discussed above, the application of TLR-based genetic engineering strategies may also provide new options for cancer immunotherapy. Since previous experiences with other costimulatory domains showed the impact of the domain architecture of engineered systems on the clinical outcome, it is necessary for future studies to make a head-to-head comparison between TLR-containing engineered receptors with other synthetic structures in preclinical and clinical settings to elucidate the characteristics of TLR-derived signals in the engineered immune cell therapies and its impact in the clinical outcome.</p></sec></body><back><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there is no conflict of interest regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J. D.</given-names></name></person-group><article-title>Cancer immunotherapy using checkpoint blockade</article-title><source><italic toggle="yes">Science</italic></source><year>2018</year><volume>359</volume><issue>6382</issue><fpage>1350</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1126/science.aar4060</pub-id><pub-id pub-id-type="other">2-s2.0-85045378539</pub-id><pub-id pub-id-type="pmid">29567705</pub-id><pub-id pub-id-type="pmcid">PMC7391259</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Q.</given-names></name></person-group><article-title>Current progress in CAR-T cell therapy for hematological malignancies</article-title><source><italic toggle="yes">Journal of Cancer</italic></source><year>2021</year><volume>12</volume><issue>2</issue><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.7150/jca.48976</pub-id><pub-id pub-id-type="pmid">33391429</pub-id><pub-id pub-id-type="pmcid">PMC7738987</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lim</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Staudt</surname><given-names>L. M.</given-names></name></person-group><article-title>Toll-like receptor signaling</article-title><source><italic toggle="yes">Cold Spring Harbor Perspectives in Biology</italic></source><year>2013</year><volume>5</volume><issue>1</issue><fpage>p. a011247</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a011247</pub-id><pub-id pub-id-type="other">2-s2.0-84872050382</pub-id><pub-id pub-id-type="pmid">23284045</pub-id><pub-id pub-id-type="pmcid">PMC3579400</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>G.</given-names></name></person-group><article-title>TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy</article-title><source><italic toggle="yes">Cellular &amp; Molecular Immunology</italic></source><year>2018</year><volume>15</volume><issue>5</issue><fpage>428</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1038/cmi.2018.4</pub-id><pub-id pub-id-type="other">2-s2.0-85050994830</pub-id><pub-id pub-id-type="pmid">29553135</pub-id><pub-id pub-id-type="pmcid">PMC6068099</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hatscher</surname><given-names>L.</given-names></name><name name-style="western"><surname>Heger</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dudziak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lehmann</surname><given-names>C. H. K.</given-names></name></person-group><article-title>Harnessing the complete repertoire of conventional dendritic cell functions for cancer immunotherapy</article-title><source><italic toggle="yes">Pharmaceutics</italic></source><year>2020</year><volume>12</volume><issue>7</issue><fpage>p. 663</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics12070663</pub-id><pub-id pub-id-type="pmid">32674488</pub-id><pub-id pub-id-type="pmcid">PMC7408110</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desch</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Gibbings</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Clambey</surname><given-names>E. T.</given-names></name><etal/></person-group><article-title>Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2014</year><volume>5</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/ncomms5674</pub-id><pub-id pub-id-type="other">2-s2.0-84907302142</pub-id><pub-id pub-id-type="pmcid">PMC4153365</pub-id><pub-id pub-id-type="pmid">25135627</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haddad</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Longhi</surname><given-names>M. P.</given-names></name></person-group><article-title>Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation</article-title><source><italic toggle="yes">PLoS Biology</italic></source><year>2014</year><volume>12</volume><issue>1, article e1001759</issue><pub-id pub-id-type="doi">10.1371/journal.pbio.1001759</pub-id><pub-id pub-id-type="other">2-s2.0-84893804974</pub-id><pub-id pub-id-type="pmid">24409099</pub-id><pub-id pub-id-type="pmcid">PMC3883643</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gobbini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Couillault</surname><given-names>C.</given-names></name><etal/></person-group><article-title>IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer</article-title><source><italic toggle="yes">Science Immunology</italic></source><year>2020</year><volume>5</volume><issue>46</issue><fpage>p. eaav3942</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aav3942</pub-id><pub-id pub-id-type="pmid">32303573</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells</article-title><source><italic toggle="yes">Cellular &amp; Molecular Immunology</italic></source><year>2014</year><volume>11</volume><issue>2</issue><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1038/cmi.2013.59</pub-id><pub-id pub-id-type="other">2-s2.0-84895508673</pub-id><pub-id pub-id-type="pmid">24362470</pub-id><pub-id pub-id-type="pmcid">PMC4003380</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y. S.</given-names></name><etal/></person-group><article-title>A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine</article-title><source><italic toggle="yes">Journal for Immunotherapy of Cancer</italic></source><year>2019</year><volume>7</volume><issue>1</issue><fpage>60</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1186/s40425-019-0539-7</pub-id><pub-id pub-id-type="other">2-s2.0-85062442297</pub-id><pub-id pub-id-type="pmid">30819254</pub-id><pub-id pub-id-type="pmcid">PMC6394096</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nourizadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Masoumi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Memarian</surname><given-names>A.</given-names></name><etal/></person-group><article-title>In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC</article-title><source><italic toggle="yes">Targeted Oncology</italic></source><year>2014</year><volume>9</volume><issue>3</issue><fpage>225</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1007/s11523-013-0285-6</pub-id><pub-id pub-id-type="other">2-s2.0-84929938717</pub-id><pub-id pub-id-type="pmid">23852664</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drobits</surname><given-names>B.</given-names></name><name name-style="western"><surname>Holcmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amberg</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>2012</year><volume>122</volume><issue>2</issue><fpage>575</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1172/JCI61034</pub-id><pub-id pub-id-type="other">2-s2.0-84856521363</pub-id><pub-id pub-id-type="pmid">22251703</pub-id><pub-id pub-id-type="pmcid">PMC3266798</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lelaidier</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#236;az-Rodriguez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cordeau</surname><given-names>M.</given-names></name><etal/></person-group><article-title>TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells</article-title><source><italic toggle="yes">Oncotarget</italic></source><year>2015</year><volume>6</volume><issue>30</issue><fpage>29440</fpage><lpage>29455</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4984</pub-id><pub-id pub-id-type="other">2-s2.0-84945138235</pub-id><pub-id pub-id-type="pmid">26320191</pub-id><pub-id pub-id-type="pmcid">PMC4745738</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prins</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Craft</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bruhn</surname><given-names>K. W.</given-names></name><etal/></person-group><article-title>The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2006</year><volume>176</volume><issue>1</issue><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.1.157</pub-id><pub-id pub-id-type="other">2-s2.0-29644446061</pub-id><pub-id pub-id-type="pmid">16365406</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramakrishna</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vasilakos</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Tario</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Keler</surname><given-names>T.</given-names></name></person-group><article-title>Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells</article-title><source><italic toggle="yes">Journal of Translational Medicine</italic></source><year>2007</year><volume>5</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1479-5876-5-5</pub-id><pub-id pub-id-type="other">2-s2.0-33846987932</pub-id><pub-id pub-id-type="pmcid">PMC1794405</pub-id><pub-id pub-id-type="pmid">17254349</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sica</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name></person-group><article-title>Macrophage plasticity and polarization: in vivo veritas</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>2012</year><volume>122</volume><issue>3</issue><fpage>787</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1172/JCI59643</pub-id><pub-id pub-id-type="other">2-s2.0-84857883847</pub-id><pub-id pub-id-type="pmid">22378047</pub-id><pub-id pub-id-type="pmcid">PMC3287223</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vidyarthi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Agnihotri</surname><given-names>T.</given-names></name><etal/></person-group><article-title>TLR-3 stimulation skews M2 macrophages to M1 through IFN-<italic toggle="yes">&#945;&#946;</italic> signaling and restricts tumor progression</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2018</year><volume>9</volume><fpage>p. 1650</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01650</pub-id><pub-id pub-id-type="other">2-s2.0-85050313647</pub-id><pub-id pub-id-type="pmcid">PMC6060442</pub-id><pub-id pub-id-type="pmid">30072995</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>E.</given-names></name><name name-style="western"><surname>Speth</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christopoulos</surname><given-names>P. F.</given-names></name><etal/></person-group><article-title>Both type I and type II interferons can activate antitumor M1 macrophages when combined with TLR stimulation</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2018</year><volume>9</volume><pub-id pub-id-type="doi">10.3389/fimmu.2018.02520</pub-id><pub-id pub-id-type="other">2-s2.0-85056335535</pub-id><pub-id pub-id-type="pmcid">PMC6224375</pub-id><pub-id pub-id-type="pmid">30450098</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers</article-title><source><italic toggle="yes">Biomaterials</italic></source><year>2013</year><volume>34</volume><issue>3</issue><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.09.062</pub-id><pub-id pub-id-type="other">2-s2.0-84868471869</pub-id><pub-id pub-id-type="pmid">23107297</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Shiau</surname><given-names>A. L.</given-names></name></person-group><article-title>Toll-like receptor 4 signaling promotes tumor growth</article-title><source><italic toggle="yes">Journal of Immunotherapy</italic></source><year>2010</year><volume>33</volume><issue>1</issue><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181b7a0a4</pub-id><pub-id pub-id-type="other">2-s2.0-74349124255</pub-id><pub-id pub-id-type="pmid">19952954</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellora</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castriconi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dondero</surname><given-names>A.</given-names></name><etal/></person-group><article-title>TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2014</year><volume>44</volume><issue>6</issue><fpage>1814</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1002/eji.201344130</pub-id><pub-id pub-id-type="other">2-s2.0-84901832190</pub-id><pub-id pub-id-type="pmid">24510590</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamilton</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bosiljcic</surname><given-names>M.</given-names></name><name name-style="western"><surname>LePard</surname><given-names>N. E.</given-names></name><etal/></person-group><article-title>Macrophages are more potent immune suppressors ex vivo than immature myeloid-derived suppressor cells induced by metastatic murine mammary carcinomas</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2014</year><volume>192</volume><issue>1</issue><fpage>512</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300096</pub-id><pub-id pub-id-type="other">2-s2.0-84891059452</pub-id><pub-id pub-id-type="pmid">24285836</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lynn</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>Thorpe</surname><given-names>P. E.</given-names></name></person-group><article-title>Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation</article-title><source><italic toggle="yes">Cancer Immunology Research</italic></source><year>2013</year><volume>1</volume><issue>4</issue><fpage>256</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0073</pub-id><pub-id pub-id-type="other">2-s2.0-84890933692</pub-id><pub-id pub-id-type="pmid">24777853</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages</article-title><source><italic toggle="yes">Cancer Letters</italic></source><year>2020</year><volume>469</volume><fpage>173</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.10.020</pub-id><pub-id pub-id-type="pmid">31629935</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>M&#252;ller</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tufa</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#252;hlradt</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>R.</given-names></name></person-group><article-title>The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2015</year><volume>64</volume><issue>9</issue><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1007/s00262-015-1723-3</pub-id><pub-id pub-id-type="other">2-s2.0-84939567874</pub-id><pub-id pub-id-type="pmid">26036909</pub-id><pub-id pub-id-type="pmcid">PMC11028474</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Welsch</surname><given-names>T.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>D.</given-names></name><name name-style="western"><surname>M&#252;hlradt</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>B&#252;chler</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>M&#228;rten</surname><given-names>A.</given-names></name></person-group><article-title>Intratumoural injection of the toll-like receptor-2/6 agonist &#8216;macrophage-activating lipopeptide-2&#8217; in patients with pancreatic carcinoma: a phase I/II trial</article-title><source><italic toggle="yes">British Journal of Cancer</italic></source><year>2007</year><volume>97</volume><issue>5</issue><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603903</pub-id><pub-id pub-id-type="other">2-s2.0-34548316162</pub-id><pub-id pub-id-type="pmid">17667928</pub-id><pub-id pub-id-type="pmcid">PMC2360370</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>E. C.</given-names></name><etal/></person-group><article-title>TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence</article-title><source><italic toggle="yes">EMBO Molecular Medicine</italic></source><year>2014</year><volume>6</volume><issue>10</issue><fpage>1294</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.15252/emmm.201403918</pub-id><pub-id pub-id-type="other">2-s2.0-84908111132</pub-id><pub-id pub-id-type="pmid">25231413</pub-id><pub-id pub-id-type="pmcid">PMC4287933</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shojaei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oberg</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Juricke</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2009</year><volume>69</volume><issue>22</issue><fpage>8710</fpage><lpage>8717</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1602</pub-id><pub-id pub-id-type="other">2-s2.0-72249091840</pub-id><pub-id pub-id-type="pmid">19887600</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nindl</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schmook</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ulrich</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sterry</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stockfleth</surname><given-names>E.</given-names></name></person-group><article-title>Induction of apoptosis by toll-like receptor-7 agonist in tissue cultures</article-title><source><italic toggle="yes">The British Journal of Dermatology</italic></source><year>2003</year><volume>149</volume><issue>Suppl 66</issue><fpage>9</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1046/j.0366-077X.2003.05632.x</pub-id><pub-id pub-id-type="pmid">14616338</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Starace</surname><given-names>D.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism</article-title><source><italic toggle="yes">Carcinogenesis</italic></source><year>2008</year><volume>29</volume><issue>7</issue><fpage>1334</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn149</pub-id><pub-id pub-id-type="other">2-s2.0-49349103910</pub-id><pub-id pub-id-type="pmid">18566014</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukuda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Suico</surname><given-names>M. A.</given-names></name><etal/></person-group><article-title>TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis</article-title><source><italic toggle="yes">Cancer Science</italic></source><year>2010</year><volume>101</volume><issue>7</issue><fpage>1610</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01567.x</pub-id><pub-id pub-id-type="other">2-s2.0-77954640888</pub-id><pub-id pub-id-type="pmid">20367642</pub-id><pub-id pub-id-type="pmcid">PMC11159143</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2011</year><volume>71</volume><issue>7</issue><fpage>2466</fpage><lpage>2475</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1993</pub-id><pub-id pub-id-type="other">2-s2.0-79953320415</pub-id><pub-id pub-id-type="pmid">21427357</pub-id><pub-id pub-id-type="pmcid">PMC3074302</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-<italic toggle="yes">&#954;</italic>B activation and NO production</article-title><source><italic toggle="yes">Tumour Biology</italic></source><year>2012</year><volume>33</volume><issue>5</issue><fpage>1607</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1007/s13277-012-0416-1</pub-id><pub-id pub-id-type="other">2-s2.0-84868116835</pub-id><pub-id pub-id-type="pmid">22739939</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchta</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>G. A.</given-names></name></person-group><article-title>Toll-like receptors and B cells: functions and mechanisms</article-title><source><italic toggle="yes">Immunologic Research</italic></source><year>2014</year><volume>59</volume><issue>1-3</issue><fpage>12</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s12026-014-8523-2</pub-id><pub-id pub-id-type="other">2-s2.0-84905757415</pub-id><pub-id pub-id-type="pmid">24847763</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Hsing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hostager</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Jalukar</surname><given-names>S. V.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Tomai</surname><given-names>M. A.</given-names></name></person-group><article-title>Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2000</year><volume>165</volume><issue>10</issue><fpage>5552</fpage><lpage>5557</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.165.10.5552</pub-id><pub-id pub-id-type="other">2-s2.0-0034669965</pub-id><pub-id pub-id-type="pmid">11067909</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name></person-group><article-title>TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors</article-title><source><italic toggle="yes">Journal of Clinical Immunology</italic></source><year>2011</year><volume>31</volume><issue>1</issue><fpage>89</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1007/s10875-010-9456-8</pub-id><pub-id pub-id-type="other">2-s2.0-79953892799</pub-id><pub-id pub-id-type="pmid">20821041</pub-id><pub-id pub-id-type="pmcid">PMC3064903</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genestier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Taillardet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mondiere</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gheit</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bella</surname><given-names>C.</given-names></name><name name-style="western"><surname>Defrance</surname><given-names>T.</given-names></name></person-group><article-title>TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2007</year><volume>178</volume><issue>12</issue><fpage>7779</fpage><lpage>7786</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.12.7779</pub-id><pub-id pub-id-type="other">2-s2.0-34250192856</pub-id><pub-id pub-id-type="pmid">17548615</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gerth</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>S. L.</given-names></name></person-group><article-title>CpG DNA redirects class-switching towards &#8220;Th1-like&#8221; Ig isotype production via TLR9 and MyD88</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2004</year><volume>34</volume><issue>5</issue><fpage>1483</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1002/eji.200324736</pub-id><pub-id pub-id-type="other">2-s2.0-2942748202</pub-id><pub-id pub-id-type="pmid">15114682</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lederman</surname><given-names>M.&#8196;. M.</given-names></name><name name-style="western"><surname>Harding</surname><given-names>C.&#8196;. V.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mohner</surname><given-names>R.&#8196;. J.</given-names></name><name name-style="western"><surname>Sieg</surname><given-names>S.&#8196;. F.</given-names></name></person-group><article-title>TLR9 stimulation drives na&#239;ve B cells to proliferate and to attain enhanced antigen presenting function</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2007</year><volume>37</volume><issue>8</issue><fpage>2205</fpage><lpage>2213</lpage><pub-id pub-id-type="doi">10.1002/eji.200636984</pub-id><pub-id pub-id-type="other">2-s2.0-34547881895</pub-id><pub-id pub-id-type="pmid">17621369</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>K. N.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>M.</given-names></name><etal/></person-group><article-title>APC-independent activation of NK cells by the toll-like receptor 3 agonist double-stranded RNA</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2004</year><volume>172</volume><issue>1</issue><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.1.138</pub-id><pub-id pub-id-type="other">2-s2.0-0346734195</pub-id><pub-id pub-id-type="pmid">14688319</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pries</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kesselring</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wulff</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wollenberg</surname><given-names>B.</given-names></name></person-group><article-title>Head and neck cancer triggers the internalization of TLR3 in natural killer cells</article-title><source><italic toggle="yes">International Journal of Molecular Medicine</italic></source><year>2007</year><volume>20</volume><issue>4</issue><fpage>493</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">17786279</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorski</surname><given-names>K. S.</given-names></name><name name-style="western"><surname>Waller</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Bjornton-Severson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists</article-title><source><italic toggle="yes">International Immunology</italic></source><year>2006</year><volume>18</volume><issue>7</issue><fpage>1115</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxl046</pub-id><pub-id pub-id-type="other">2-s2.0-33745241135</pub-id><pub-id pub-id-type="pmid">16728430</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>O. M.</given-names></name><name name-style="western"><surname>Athie-Morales</surname><given-names>V.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Gardiner</surname><given-names>C. M.</given-names></name></person-group><article-title>TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2005</year><volume>175</volume><issue>3</issue><fpage>1636</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.3.1636</pub-id><pub-id pub-id-type="pmid">16034103</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabel</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Sondak</surname><given-names>V. K.</given-names></name></person-group><article-title>Pros and cons of adjuvant interferon in the treatment of melanoma</article-title><source><italic toggle="yes">The Oncologist</italic></source><year>2003</year><volume>8</volume><issue>5</issue><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.8-5-451</pub-id><pub-id pub-id-type="other">2-s2.0-0141888522</pub-id><pub-id pub-id-type="pmid">14530498</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lester</surname><given-names>R. T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.-D.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>T. B.</given-names></name><etal/></person-group><article-title>Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection</article-title><source><italic toggle="yes">AIDS</italic></source><year>2008</year><volume>22</volume><issue>6</issue><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3282f4de35</pub-id><pub-id pub-id-type="other">2-s2.0-41349107635</pub-id><pub-id pub-id-type="pmid">18356597</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice</article-title><source><italic toggle="yes">Cellular &amp; Molecular Immunology</italic></source><year>2010</year><volume>7</volume><issue>5</issue><fpage>381</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/cmi.2010.30</pub-id><pub-id pub-id-type="other">2-s2.0-77957680668</pub-id><pub-id pub-id-type="pmid">20543857</pub-id><pub-id pub-id-type="pmcid">PMC4002679</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gad</surname><given-names>E.</given-names></name><etal/></person-group><article-title>TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2011</year><volume>17</volume><issue>21</issue><fpage>6742</fpage><lpage>6753</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1142</pub-id><pub-id pub-id-type="other">2-s2.0-80455144500</pub-id><pub-id pub-id-type="pmid">21918170</pub-id><pub-id pub-id-type="pmcid">PMC3206987</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crellin</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>R. V.</given-names></name><name name-style="western"><surname>Hadisfar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Allan</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>T. S.</given-names></name><name name-style="western"><surname>Levings</surname><given-names>M. K.</given-names></name></person-group><article-title>Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2005</year><volume>175</volume><issue>12</issue><fpage>8051</fpage><lpage>8059</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.12.8051</pub-id><pub-id pub-id-type="other">2-s2.0-29144534608</pub-id><pub-id pub-id-type="pmid">16339542</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Turka</surname><given-names>L. A.</given-names></name></person-group><article-title>The contribution of direct TLR signaling to T cell responses</article-title><source><italic toggle="yes">Immunologic Research</italic></source><year>2009</year><volume>45</volume><issue>1</issue><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s12026-009-8113-x</pub-id><pub-id pub-id-type="other">2-s2.0-70349583503</pub-id><pub-id pub-id-type="pmid">19597998</pub-id><pub-id pub-id-type="pmcid">PMC4486050</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cottalorda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verschelde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mar&#231;ais</surname><given-names>A.</given-names></name><etal/></person-group><article-title>TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>2006</year><volume>36</volume><issue>7</issue><fpage>1684</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1002/eji.200636181</pub-id><pub-id pub-id-type="other">2-s2.0-33746256898</pub-id><pub-id pub-id-type="pmid">16761317</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caron</surname><given-names>G.</given-names></name><name name-style="western"><surname>Duluc</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fr&#233;maux</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2005</year><volume>175</volume><issue>3</issue><fpage>1551</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.3.1551</pub-id><pub-id pub-id-type="pmid">16034093</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Toll-like receptor 7 activation enhances CD8+ T cell effector functions by promoting cellular glycolysis</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2019</year><volume>10</volume><pub-id pub-id-type="doi">10.3389/fimmu.2019.02191</pub-id><pub-id pub-id-type="other">2-s2.0-85072760545</pub-id><pub-id pub-id-type="pmcid">PMC6751247</pub-id><pub-id pub-id-type="pmid">31572396</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asprodites</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Velasco&#8208;Gonzalez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sanchez&#8208;Perez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>E.</given-names></name></person-group><article-title>Engagement of toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity</article-title><source><italic toggle="yes">The FASEB Journal</italic></source><year>2008</year><volume>22</volume><issue>10</issue><fpage>3628</fpage><lpage>3637</lpage><pub-id pub-id-type="doi">10.1096/fj.08-108274</pub-id><pub-id pub-id-type="other">2-s2.0-54049096321</pub-id><pub-id pub-id-type="pmid">18587008</pub-id><pub-id pub-id-type="pmcid">PMC2537425</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R.</given-names></name><name name-style="western"><surname>Asprodites</surname><given-names>N.</given-names></name><name name-style="western"><surname>Velasco-Gonzalez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Davila</surname><given-names>E.</given-names></name></person-group><article-title>When toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function</article-title><source><italic toggle="yes">Blood</italic></source><year>2010</year><volume>116</volume><issue>18</issue><fpage>3494</fpage><lpage>3504</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-02-268169</pub-id><pub-id pub-id-type="other">2-s2.0-78149353783</pub-id><pub-id pub-id-type="pmid">20696947</pub-id><pub-id pub-id-type="pmcid">PMC2981476</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabiasco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dev&#234;vre</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rufer</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2006</year><volume>177</volume><issue>12</issue><fpage>8708</fpage><lpage>8713</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.177.12.8708</pub-id><pub-id pub-id-type="other">2-s2.0-33845427951</pub-id><pub-id pub-id-type="pmid">17142772</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salem</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Diaz-Montero</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>el-Naggar</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>D. J.</given-names></name></person-group><article-title>The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into na&#239;ve recipient mice</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2009</year><volume>27</volume><issue>4</issue><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.11.013</pub-id><pub-id pub-id-type="other">2-s2.0-57749186869</pub-id><pub-id pub-id-type="pmid">19027047</pub-id><pub-id pub-id-type="pmcid">PMC3072892</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>G.</given-names></name></person-group><article-title>Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function</article-title><source><italic toggle="yes">Science</italic></source><year>2005</year><volume>309</volume><issue>5739</issue><fpage>1380</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1126/science.1113401</pub-id><pub-id pub-id-type="other">2-s2.0-23944509107</pub-id><pub-id pub-id-type="pmid">16123302</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutmuller</surname><given-names>R. P.</given-names></name><name name-style="western"><surname>den Brok</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Toll-like receptor 2 controls expansion and function of regulatory T cells</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>2006</year><volume>116</volume><issue>2</issue><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1172/JCI25439</pub-id><pub-id pub-id-type="other">2-s2.0-32444432610</pub-id><pub-id pub-id-type="pmid">16424940</pub-id><pub-id pub-id-type="pmcid">PMC1332026</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberg</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>T. T. H.</given-names></name><name name-style="western"><surname>Ussat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kabelitz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wesch</surname><given-names>D.</given-names></name></person-group><article-title>Differential but direct abolishment of human regulatory T cell suppressive capacity by various TLR2 ligands</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2010</year><volume>184</volume><issue>9</issue><fpage>4733</fpage><lpage>4740</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0804279</pub-id><pub-id pub-id-type="other">2-s2.0-77954503874</pub-id><pub-id pub-id-type="pmid">20363971</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Komai-Koma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>F. Y.</given-names></name></person-group><article-title>Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2006</year><volume>103</volume><issue>18</issue><fpage>7048</fpage><lpage>7053</lpage><pub-id pub-id-type="doi">10.1073/pnas.0601554103</pub-id><pub-id pub-id-type="other">2-s2.0-33646487278</pub-id><pub-id pub-id-type="pmid">16632602</pub-id><pub-id pub-id-type="pmcid">PMC1444884</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Recent clinical trends in toll-like receptor targeting therapeutics</article-title><source><italic toggle="yes">Medicinal Research Reviews</italic></source><year>2019</year><volume>39</volume><issue>3</issue><fpage>1053</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1002/med.21553</pub-id><pub-id pub-id-type="other">2-s2.0-85056870029</pub-id><pub-id pub-id-type="pmid">30450666</pub-id><pub-id pub-id-type="pmcid">PMC6587958</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>R. S.</given-names></name></person-group><article-title>Immunological evaluation of colonic delivered hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles</article-title><source><italic toggle="yes">International Immunopharmacology</italic></source><year>2016</year><volume>39</volume><fpage>343</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2016.08.007</pub-id><pub-id pub-id-type="other">2-s2.0-84981295083</pub-id><pub-id pub-id-type="pmid">27526270</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheiermann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D. M.</given-names></name></person-group><article-title>Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2014</year><volume>32</volume><issue>48</issue><fpage>6377</fpage><lpage>6389</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.065</pub-id><pub-id pub-id-type="other">2-s2.0-84908592762</pub-id><pub-id pub-id-type="pmid">24975812</pub-id><pub-id pub-id-type="pmcid">PMC4252359</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunes</surname><given-names>F. P. B.</given-names></name><name name-style="western"><surname>Alberca&#8208;Cust&#243;dio</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>E.</given-names></name><etal/></person-group><article-title>TLR9 agonist adsorbed to alum adjuvant prevents asthma-like responses induced by Blomia tropicalis mite extract</article-title><source><italic toggle="yes">Journal of Leukocyte Biology</italic></source><year>2019</year><volume>106</volume><issue>3</issue><fpage>653</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1002/JLB.MA1218-475RR</pub-id><pub-id pub-id-type="other">2-s2.0-85069800573</pub-id><pub-id pub-id-type="pmid">31329326</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royer</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dietsch</surname><given-names>G. N.</given-names></name><name name-style="western"><surname>Hershberg</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>E. G.</given-names></name></person-group><article-title>VTX-1463, a novel TLR-8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs</article-title><source><italic toggle="yes">Immunity, Inflammation and Disease</italic></source><year>2016</year><volume>4</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1002/iid3.91</pub-id><pub-id pub-id-type="other">2-s2.0-85061675953</pub-id><pub-id pub-id-type="pmid">27042301</pub-id><pub-id pub-id-type="pmcid">PMC4768068</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hussein</surname><given-names>W. M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T. Y.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name></person-group><article-title>Toll-like receptor agonists: a patent review (2011&#8211;2013)</article-title><source><italic toggle="yes">Expert Opinion on Therapeutic Patents</italic></source><year>2014</year><volume>24</volume><issue>4</issue><fpage>453</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1517/13543776.2014.880691</pub-id><pub-id pub-id-type="other">2-s2.0-84896460595</pub-id><pub-id pub-id-type="pmid">24456079</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manavalan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>T. H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Roles of toll-like receptors in cancer: a double-edged sword for defense and offense</article-title><source><italic toggle="yes">Archives of Pharmacal Research</italic></source><year>2012</year><volume>35</volume><issue>8</issue><fpage>1297</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1007/s12272-012-0802-7</pub-id><pub-id pub-id-type="other">2-s2.0-84868101247</pub-id><pub-id pub-id-type="pmid">22941474</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Simons</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Griffith</surname><given-names>T. S.</given-names></name></person-group><source><italic toggle="yes">Role of Neutrophils in BCG Immunotherapy for Bladder Cancer</italic></source><year>2008</year><publisher-loc>Elsevier</publisher-loc><publisher-name>In Urologic Oncology: Seminars and Original Investigations</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.urolonc.2007.11.031</pub-id><pub-id pub-id-type="pmcid">PMC2493065</pub-id><pub-id pub-id-type="pmid">18593617</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pretto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tagliabue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Balsari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sfondrini</surname><given-names>L.</given-names></name></person-group><article-title>Exploiting poly(I:C) to induce cancer cell apoptosis</article-title><source><italic toggle="yes">Cancer Biology &amp; Therapy</italic></source><year>2017</year><volume>18</volume><issue>10</issue><fpage>747</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1080/15384047.2017.1373220</pub-id><pub-id pub-id-type="other">2-s2.0-85031787450</pub-id><pub-id pub-id-type="pmid">28881163</pub-id><pub-id pub-id-type="pmcid">PMC5678690</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name></person-group><article-title>A toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy</article-title><source><italic toggle="yes">Advanced Drug Delivery Reviews</italic></source><year>2019</year><volume>147</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2019.07.008</pub-id><pub-id pub-id-type="other">2-s2.0-85069827589</pub-id><pub-id pub-id-type="pmid">31302192</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2012</year><volume>7</volume><issue>12, article e51618</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0051618</pub-id><pub-id pub-id-type="other">2-s2.0-84871700730</pub-id><pub-id pub-id-type="pmid">23284726</pub-id><pub-id pub-id-type="pmcid">PMC3532059</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>J.</given-names></name><name name-style="western"><surname>ter Meulen</surname><given-names>J.</given-names></name></person-group><article-title>Intratumoral injection of G100 (TLR4 agonist glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity</article-title><year>2016</year><publisher-loc>AACR</publisher-loc></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haderski</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Kandar</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Brackett</surname><given-names>C. M.</given-names></name><etal/></person-group><article-title>TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2020</year><volume>15</volume><issue>2, article e0227940</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0227940</pub-id><pub-id pub-id-type="pmid">32027657</pub-id><pub-id pub-id-type="pmcid">PMC7004342</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mett</surname><given-names>V.</given-names></name><name name-style="western"><surname>Komarova</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Mobilan: a recombinant adenovirus carrying toll-like receptor 5 self-activating cassette for cancer immunotherapy</article-title><source><italic toggle="yes">Oncogene</italic></source><year>2018</year><volume>37</volume><issue>4</issue><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1038/onc.2017.346</pub-id><pub-id pub-id-type="other">2-s2.0-85041091650</pub-id><pub-id pub-id-type="pmid">28967901</pub-id><pub-id pub-id-type="pmcid">PMC5799711</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Witte</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>van de Sande</surname><given-names>A. J. M.</given-names></name><name name-style="western"><surname>van Beekhuizen</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Koeneman</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Kruse</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Gerestein</surname><given-names>C. G.</given-names></name></person-group><article-title>Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review</article-title><source><italic toggle="yes">Gynecologic Oncology</italic></source><year>2015</year><volume>139</volume><issue>2</issue><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1016/j.ygyno.2015.08.018</pub-id><pub-id pub-id-type="other">2-s2.0-84952630457</pub-id><pub-id pub-id-type="pmid">26335596</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>D.</given-names></name></person-group><source><italic toggle="yes">IMPALA, a Randomized Phase III Study in Patients with Metastatic Colorectal Carcinoma: Immunomodulatory Maintenance Therapy with TLR-9 Agonist MGN1703</italic></source><year>2015</year><publisher-name>American Society of Clinical Oncology</publisher-name></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dowling</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Mansell</surname><given-names>A.</given-names></name></person-group><article-title>Toll-like receptors: the Swiss army knife of immunity and vaccine development</article-title><source><italic toggle="yes">Clinical &amp; translational immunology</italic></source><year>2016</year><volume>5</volume><issue>5, article e85</issue><pub-id pub-id-type="doi">10.1038/cti.2016.22</pub-id><pub-id pub-id-type="other">2-s2.0-85065699055</pub-id><pub-id pub-id-type="pmid">27350884</pub-id><pub-id pub-id-type="pmcid">PMC4910119</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudek</surname><given-names>A. Z.</given-names></name><name name-style="western"><surname>Yunis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>L. I.</given-names></name><etal/></person-group><article-title>First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2007</year><volume>13</volume><issue>23</issue><fpage>7119</fpage><lpage>7125</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1443</pub-id><pub-id pub-id-type="other">2-s2.0-37249041922</pub-id><pub-id pub-id-type="pmid">18056192</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Houot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name></person-group><article-title>T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy</article-title><source><italic toggle="yes">Blood</italic></source><year>2009</year><volume>113</volume><issue>15</issue><fpage>3546</fpage><lpage>3552</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-07-170274</pub-id><pub-id pub-id-type="other">2-s2.0-65349153756</pub-id><pub-id pub-id-type="pmid">18941113</pub-id><pub-id pub-id-type="pmcid">PMC2668854</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.-K.</given-names></name></person-group><source><italic toggle="yes">TLR Agonists as Adjuvants for Cancer Vaccines, in Regulation of Inflammatory Signaling in Health and Disease</italic></source><year>2017</year><publisher-loc>Springer</publisher-loc></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marabelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kohrt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name></person-group><article-title>Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2013</year><volume>19</volume><issue>19</issue><fpage>5261</fpage><lpage>5263</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-1923</pub-id><pub-id pub-id-type="other">2-s2.0-84886405297</pub-id><pub-id pub-id-type="pmid">23965900</pub-id><pub-id pub-id-type="pmcid">PMC3817012</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Schmoll</surname><given-names>H.-J.</given-names></name></person-group><source><italic toggle="yes">Maintenance Therapy with the TLR-9 Agonist MGN1703 in the Phase II IMPACT Study of Metastatic Colorectal Cancer Patients: A Subgroup with Improved Overall Survival</italic></source><year>2015</year><publisher-name>American Society of Clinical Oncology</publisher-name></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmoll</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Wittig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial</article-title><source><italic toggle="yes">Journal of Cancer Research and Clinical Oncology</italic></source><year>2014</year><volume>140</volume><issue>9</issue><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1007/s00432-014-1682-7</pub-id><pub-id pub-id-type="other">2-s2.0-84902676837</pub-id><pub-id pub-id-type="pmid">24816725</pub-id><pub-id pub-id-type="pmcid">PMC4131138</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wittig</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scheithauer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schmoll</surname><given-names>H. J.</given-names></name></person-group><article-title>MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside</article-title><source><italic toggle="yes">Critical Reviews in Oncology/Hematology</italic></source><year>2015</year><volume>94</volume><issue>1</issue><fpage>31</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2014.12.002</pub-id><pub-id pub-id-type="other">2-s2.0-84926089064</pub-id><pub-id pub-id-type="pmid">25577571</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kandimalla</surname><given-names>E.</given-names></name></person-group><source><italic toggle="yes">Synthetic Agonists of Toll-Like Receptors 7, 8 and 9</italic></source><year>2007</year><publisher-name>Portland Press Ltd</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BST0351461</pub-id><pub-id pub-id-type="pmid">18031246</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non&#8211;small-cell lung cancer</article-title><source><italic toggle="yes">Journal of Clinical Oncology</italic></source><year>2011</year><volume>29</volume><issue>19</issue><fpage>2667</fpage><lpage>2674</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.32.8971</pub-id><pub-id pub-id-type="other">2-s2.0-79960110662</pub-id><pub-id pub-id-type="pmid">21632509</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapp</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Distinct immunological activation profiles of dSLIM&#174; and ProMune&#174; depend on their different structural context</article-title><source><italic toggle="yes">Immunity, Inflammation and Disease</italic></source><year>2016</year><volume>4</volume><issue>4</issue><fpage>446</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1002/iid3.126</pub-id><pub-id pub-id-type="other">2-s2.0-85029102600</pub-id><pub-id pub-id-type="pmid">27980779</pub-id><pub-id pub-id-type="pmcid">PMC5134728</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krieg</surname><given-names>A. M.</given-names></name></person-group><article-title>Toll-like receptor 9 (TLR9) agonists in the treatment of cancer</article-title><source><italic toggle="yes">Oncogene</italic></source><year>2008</year><volume>27</volume><issue>2</issue><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210911</pub-id><pub-id pub-id-type="other">2-s2.0-37849002321</pub-id><pub-id pub-id-type="pmid">18176597</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manegold</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Zandwijk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Szczesna</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer</article-title><source><italic toggle="yes">Annals of Oncology</italic></source><year>2012</year><volume>23</volume><issue>1</issue><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdr030</pub-id><pub-id pub-id-type="other">2-s2.0-84855184648</pub-id><pub-id pub-id-type="pmid">21464154</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Conkling</surname><given-names>P.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D. A.</given-names></name><etal/></person-group><article-title>Antitumor activity and safety of combination therapy with the toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2014</year><volume>63</volume><issue>8</issue><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1007/s00262-014-1547-6</pub-id><pub-id pub-id-type="other">2-s2.0-84906791645</pub-id><pub-id pub-id-type="pmid">24770667</pub-id><pub-id pub-id-type="pmcid">PMC11028443</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato-Kaneko</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer</article-title><source><italic toggle="yes">JCI Insight</italic></source><year>2017</year><volume>2</volume><issue>18</issue><pub-id pub-id-type="doi">10.1172/jci.insight.93397</pub-id><pub-id pub-id-type="other">2-s2.0-85036635837</pub-id><pub-id pub-id-type="pmid">28931759</pub-id><pub-id pub-id-type="pmcid">PMC5621908</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reilley</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ager</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Curran</surname><given-names>M. A.</given-names></name></person-group><article-title>TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma</article-title><source><italic toggle="yes">Journal for Immunotherapy of Cancer</italic></source><year>2019</year><volume>7</volume><issue>1</issue><fpage>p. 323</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0811-x</pub-id><pub-id pub-id-type="pmid">31771649</pub-id><pub-id pub-id-type="pmcid">PMC6880482</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patra</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Recent progress in the development of toll-like receptor (TLR) antagonists</article-title><source><italic toggle="yes">Expert Opinion on Therapeutic Patents</italic></source><year>2016</year><volume>26</volume><issue>6</issue><fpage>719</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1080/13543776.2016.1185415</pub-id><pub-id pub-id-type="other">2-s2.0-84975291111</pub-id><pub-id pub-id-type="pmid">27136061</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steinhagen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kinjo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bode</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D. M.</given-names></name></person-group><article-title>TLR-based immune adjuvants</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2011</year><volume>29</volume><issue>17</issue><fpage>3341</fpage><lpage>3355</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.08.002</pub-id><pub-id pub-id-type="other">2-s2.0-79954582124</pub-id><pub-id pub-id-type="pmid">20713100</pub-id><pub-id pub-id-type="pmcid">PMC3000864</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murata</surname><given-names>M.</given-names></name></person-group><article-title>Activation of toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors</article-title><source><italic toggle="yes">Cancer Science</italic></source><year>2008</year><volume>99</volume><issue>7</issue><fpage>1435</fpage><lpage>1440</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00832.x</pub-id><pub-id pub-id-type="other">2-s2.0-44449120076</pub-id><pub-id pub-id-type="pmid">18452561</pub-id><pub-id pub-id-type="pmcid">PMC11159084</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyauchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models</article-title><source><italic toggle="yes">Drug Discoveries &amp; Therapeutics</italic></source><year>2012</year><volume>6</volume><issue>4</issue><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">23006993</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reilly</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>M. H.</given-names></name><etal/></person-group><article-title>Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody</article-title><source><italic toggle="yes">Clinical Pharmacology and Therapeutics</italic></source><year>2013</year><volume>94</volume><issue>5</issue><fpage>593</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.150</pub-id><pub-id pub-id-type="other">2-s2.0-84886725015</pub-id><pub-id pub-id-type="pmid">23880971</pub-id><pub-id pub-id-type="pmcid">PMC3805945</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ammi</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Waele</surname><given-names>J.</given-names></name><name name-style="western"><surname>Willemen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs</article-title><source><italic toggle="yes">Pharmacology &amp; Therapeutics</italic></source><year>2015</year><volume>146</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.09.010</pub-id><pub-id pub-id-type="other">2-s2.0-84921289568</pub-id><pub-id pub-id-type="pmid">25281915</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melssen</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Petroni</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Chianese-Bullock</surname><given-names>K. A.</given-names></name><etal/></person-group><article-title>A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients</article-title><source><italic toggle="yes">Journal for Immunotherapy of Cancer</italic></source><year>2019</year><volume>7</volume><issue>1</issue><fpage>p. 163</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0625-x</pub-id><pub-id pub-id-type="other">2-s2.0-85068462372</pub-id><pub-id pub-id-type="pmid">31248461</pub-id><pub-id pub-id-type="pmcid">PMC6598303</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navabi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jasani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reece</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A clinical grade poly I:C-analogue (Ampligen<sup>&#174;</sup>) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2009</year><volume>27</volume><issue>1</issue><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.024</pub-id><pub-id pub-id-type="other">2-s2.0-56949108633</pub-id><pub-id pub-id-type="pmid">18977262</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kuznik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jerala</surname><given-names>R.</given-names></name></person-group><article-title>Therapeutic applications of nucleic acids as ligands for toll-like receptors</article-title><source><italic toggle="yes">Current Opinion in Molecular Therapeutics</italic></source><year>2009</year><volume>11</volume><issue>2</issue><fpage>133</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">19330719</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takashima</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models</article-title><source><italic toggle="yes">Cancer Science</italic></source><year>2018</year><volume>109</volume><issue>7</issue><fpage>2119</fpage><lpage>2129</lpage><pub-id pub-id-type="doi">10.1111/cas.13649</pub-id><pub-id pub-id-type="other">2-s2.0-85049323187</pub-id><pub-id pub-id-type="pmid">29791768</pub-id><pub-id pub-id-type="pmcid">PMC6029830</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tatematsu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name></person-group><article-title>Toll-like receptor 3 signal in dendritic cells benefits cancer immunotherapy</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2017</year><volume>8</volume><pub-id pub-id-type="doi">10.3389/fimmu.2017.01897</pub-id><pub-id pub-id-type="other">2-s2.0-85038969440</pub-id><pub-id pub-id-type="pmcid">PMC5742578</pub-id><pub-id pub-id-type="pmid">29312355</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>T. K.</given-names></name><name name-style="western"><surname>Hobbs</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Driver</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>E. R.</given-names></name></person-group><article-title>The toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection</article-title><source><italic toggle="yes">Infection and Immunity</italic></source><year>2011</year><volume>79</volume><issue>9</issue><fpage>3576</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1128/IAI.00022-11</pub-id><pub-id pub-id-type="other">2-s2.0-80052305941</pub-id><pub-id pub-id-type="pmid">21646453</pub-id><pub-id pub-id-type="pmcid">PMC3165493</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coler</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>The TBVPX-113 Study Team</surname></name><name name-style="western"><surname>Day</surname><given-names>T. A.</given-names></name><etal/></person-group><article-title>The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial</article-title><source><italic toggle="yes">NPJ Vaccines</italic></source><year>2018</year><volume>3</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41541-018-0057-5</pub-id><pub-id pub-id-type="other">2-s2.0-85052816446</pub-id><pub-id pub-id-type="pmcid">PMC6123489</pub-id><pub-id pub-id-type="pmid">30210819</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Morel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lockman</surname><given-names>L.</given-names></name><etal/></person-group><article-title>AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity</article-title><source><italic toggle="yes">Journal of Immunology</italic></source><year>2009</year><volume>183</volume><issue>10</issue><fpage>6186</fpage><lpage>6197</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901474</pub-id><pub-id pub-id-type="other">2-s2.0-77249176352</pub-id><pub-id pub-id-type="pmid">19864596</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oba</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Teramukai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maehara</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sakamoto</surname><given-names>J.</given-names></name></person-group><article-title>The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials</article-title><source><italic toggle="yes">Gastric Cancer</italic></source><year>2016</year><volume>19</volume><issue>2</issue><fpage>616</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1007/s10120-015-0489-9</pub-id><pub-id pub-id-type="other">2-s2.0-84925678972</pub-id><pub-id pub-id-type="pmid">25804300</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Federico</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pozzetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Papa</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Modulation of the innate immune response by targeting toll-like receptors: a perspective on their agonists and antagonists</article-title><source><italic toggle="yes">Journal of Medicinal Chemistry</italic></source><year>2020</year><volume>63</volume><issue>22</issue><fpage>13466</fpage><lpage>13513</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c01049</pub-id><pub-id pub-id-type="pmid">32845153</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horak</surname><given-names>F.</given-names></name></person-group><article-title>VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis</article-title><source><italic toggle="yes">Expert Opinion on Investigational Drugs</italic></source><year>2011</year><volume>20</volume><issue>7</issue><fpage>981</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1517/13543784.2011.583237</pub-id><pub-id pub-id-type="other">2-s2.0-79958832035</pub-id><pub-id pub-id-type="pmid">21548830</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zent</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Ballas</surname><given-names>Z. K.</given-names></name><etal/></person-group><article-title>Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia</article-title><source><italic toggle="yes">Leukemia &amp; Lymphoma</italic></source><year>2012</year><volume>53</volume><issue>2</issue><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.3109/10428194.2011.608451</pub-id><pub-id pub-id-type="other">2-s2.0-84863393261</pub-id><pub-id pub-id-type="pmid">21812536</pub-id><pub-id pub-id-type="pmcid">PMC3438221</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Machiels</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Kaminsky</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Phase Ib trial of the toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck</article-title><source><italic toggle="yes">Investigational New Drugs</italic></source><year>2013</year><volume>31</volume><issue>5</issue><fpage>1207</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1007/s10637-013-9933-z</pub-id><pub-id pub-id-type="other">2-s2.0-84884819741</pub-id><pub-id pub-id-type="pmid">23397499</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gallotta</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2016</year><volume>113</volume><issue>46</issue><fpage>E7240</fpage><lpage>E7249</lpage><pub-id pub-id-type="doi">10.1073/pnas.1608555113</pub-id><pub-id pub-id-type="other">2-s2.0-84995640008</pub-id><pub-id pub-id-type="pmid">27799536</pub-id><pub-id pub-id-type="pmcid">PMC5135381</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vacchelli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bloy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Aranda</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Trial Watch: immunotherapy plus radiation therapy for oncological indications</article-title><source><italic toggle="yes">Oncoimmunology</italic></source><year>2016</year><volume>5</volume><issue>9, article e1214790</issue><pub-id pub-id-type="doi">10.1080/2162402X.2016.1214790</pub-id><pub-id pub-id-type="other">2-s2.0-84986253403</pub-id><pub-id pub-id-type="pmid">27757313</pub-id><pub-id pub-id-type="pmcid">PMC5048768</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babaer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Amara</surname><given-names>S.</given-names></name><name name-style="western"><surname>McAdory</surname><given-names>B. S.</given-names></name><etal/></person-group><article-title>Oligodeoxynucleotides ODN 2006 and M362 exert potent adjuvant effect through TLR-9/-6 synergy to exaggerate mammaglobin-A peptide specific cytotoxic CD8+T lymphocyte responses against breast cancer cells</article-title><source><italic toggle="yes">Cancers (Basel)</italic></source><year>2019</year><volume>11</volume><issue>5</issue><fpage>p. 672</fpage><pub-id pub-id-type="doi">10.3390/cancers11050672</pub-id><pub-id pub-id-type="other">2-s2.0-85067039487</pub-id><pub-id pub-id-type="pmid">31091800</pub-id><pub-id pub-id-type="pmcid">PMC6562487</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><etal/></person-group><article-title>CpG ODN1826 as a promising mucin1-maltose-binding protein vaccine adjuvant induced DC maturation and enhanced antitumor immunity</article-title><source><italic toggle="yes">International Journal of Molecular Sciences</italic></source><year>2018</year><volume>19</volume><issue>3</issue><fpage>p. 920</fpage><pub-id pub-id-type="doi">10.3390/ijms19030920</pub-id><pub-id pub-id-type="other">2-s2.0-85044263147</pub-id><pub-id pub-id-type="pmid">29558459</pub-id><pub-id pub-id-type="pmcid">PMC5877781</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Minutolo</surname><given-names>N. G.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klichinsky</surname><given-names>M.</given-names></name></person-group><article-title>Macrophage-based approaches for cancer immunotherapy</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2021</year><volume>81</volume><issue>5</issue><fpage>1201</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.can-20-2990</pub-id><pub-id pub-id-type="pmid">33203697</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anguille</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Lion</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Tendeloo</surname><given-names>V. F.</given-names></name><name name-style="western"><surname>Berneman</surname><given-names>Z. N.</given-names></name></person-group><article-title>Clinical use of dendritic cells for cancer therapy</article-title><source><italic toggle="yes">The Lancet Oncology</italic></source><year>2014</year><volume>15</volume><issue>7</issue><fpage>e257</fpage><lpage>e267</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(13)70585-0</pub-id><pub-id pub-id-type="other">2-s2.0-84901405092</pub-id><pub-id pub-id-type="pmid">24872109</pub-id></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name></person-group><article-title>NK cell-based immunotherapy for cancer</article-title><source><italic toggle="yes">Seminars in Immunology</italic></source><year>2017</year><volume>31</volume><fpage>37</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2017.07.009</pub-id><pub-id pub-id-type="other">2-s2.0-85028019952</pub-id><pub-id pub-id-type="pmid">28838796</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Assadipour</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kriley</surname><given-names>I.</given-names></name><name name-style="western"><surname>Goff</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>S. A.</given-names></name></person-group><article-title>Adoptive cell therapy--tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors</article-title><source><italic toggle="yes">Seminars in Oncology</italic></source><year>2015</year><volume>42</volume><issue>4</issue><fpage>626</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2015.05.005</pub-id><pub-id pub-id-type="other">2-s2.0-84940379637</pub-id><pub-id pub-id-type="pmid">26320066</pub-id><pub-id pub-id-type="pmcid">PMC6295669</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pahlavanneshan</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of ALPP as a potential target for immunotherapy of solid tumors using gene and protein expression repositories</article-title><source><italic toggle="yes">Cell J</italic></source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.22074/cellj.2021.7299</pub-id><pub-id pub-id-type="pmcid">PMC8665984</pub-id><pub-id pub-id-type="pmid">34939766</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddadi</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Hajizadeh-Saffar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khosravi-Maharlooei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Basiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Negahdari</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baharvand</surname><given-names>H.</given-names></name></person-group><article-title>Autoimmunity as a target for chimeric immune receptor therapy: a new vision to therapeutic potential</article-title><source><italic toggle="yes">Blood Reviews</italic></source><year>2020</year><volume>41</volume><fpage>p. 100645</fpage><pub-id pub-id-type="doi">10.1016/j.blre.2019.100645</pub-id><pub-id pub-id-type="pmid">31813654</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinkove</surname><given-names>R.</given-names></name><name name-style="western"><surname>George</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dasyam</surname><given-names>N.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>A. D.</given-names></name></person-group><article-title>Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations</article-title><source><italic toggle="yes">Clinical &amp; Translational Immunology</italic></source><year>2019</year><volume>8</volume><issue>5</issue><fpage>p. e1049</fpage><pub-id pub-id-type="doi">10.1002/cti2.1049</pub-id><pub-id pub-id-type="other">2-s2.0-85065989389</pub-id><pub-id pub-id-type="pmid">31110702</pub-id><pub-id pub-id-type="pmcid">PMC6511336</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowolik</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Topp</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>S.</given-names></name><etal/></person-group><article-title>CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2006</year><volume>66</volume><issue>22</issue><fpage>10995</fpage><lpage>11004</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-0160</pub-id><pub-id pub-id-type="other">2-s2.0-33845294816</pub-id><pub-id pub-id-type="pmid">17108138</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T cells</article-title><source><italic toggle="yes">Leukemia</italic></source><year>2018</year><volume>32</volume><issue>3</issue><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.249</pub-id><pub-id pub-id-type="other">2-s2.0-85042303634</pub-id><pub-id pub-id-type="pmid">28841215</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collinson-Pautz</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies</article-title><source><italic toggle="yes">Leukemia</italic></source><year>2019</year><volume>33</volume><issue>9</issue><fpage>2195</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1038/s41375-019-0417-9</pub-id><pub-id pub-id-type="other">2-s2.0-85062320550</pub-id><pub-id pub-id-type="pmid">30816327</pub-id><pub-id pub-id-type="pmcid">PMC6756044</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Mahendravada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shinners</surname><given-names>N. P.</given-names></name><etal/></person-group><article-title>Regulated expansion and survival of chimeric antigen receptor-modified T cells using small molecule-dependent inducible MyD88/CD40</article-title><source><italic toggle="yes">Molecular Therapy</italic></source><year>2017</year><volume>25</volume><issue>9</issue><fpage>2176</fpage><lpage>2188</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.06.014</pub-id><pub-id pub-id-type="other">2-s2.0-85022043762</pub-id><pub-id pub-id-type="pmid">28697888</pub-id><pub-id pub-id-type="pmcid">PMC5589084</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davey</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Call</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Call</surname><given-names>M. J.</given-names></name></person-group><article-title>The influence of chimeric antigen receptor structural domains on clinical outcomes and associated toxicities</article-title><source><italic toggle="yes">Cancers</italic></source><year>2021</year><volume>13</volume><issue>1</issue><pub-id pub-id-type="doi">10.3390/cancers13010038</pub-id><pub-id pub-id-type="pmcid">PMC7794933</pub-id><pub-id pub-id-type="pmid">33375550</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jasinski</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Bayle</surname><given-names>J. H.</given-names></name></person-group><article-title>Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells</article-title><source><italic toggle="yes">Blood Advances</italic></source><year>2020</year><volume>4</volume><issue>9</issue><fpage>1950</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020001510</pub-id><pub-id pub-id-type="pmid">32384544</pub-id><pub-id pub-id-type="pmcid">PMC7218419</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Velazquez</surname><given-names>E. J.</given-names></name></person-group><article-title>Macrophage toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2018</year><volume>78</volume><fpage>2563</fpage><lpage>2563</lpage></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Townsend</surname><given-names>M. H.</given-names></name></person-group><article-title>MOTO-CARs&#8482;: a novel macrophage-based chimeric antigen receptor technology</article-title><source><italic toggle="yes">Cancer Research</italic></source><year>2020</year><volume>80</volume><fpage>3254</fpage><lpage>3254</lpage></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Combined adjuvant of poly I:C improves antitumor effects of CAR-T cells</article-title><source><italic toggle="yes">Frontiers in Oncology</italic></source><year>2019</year><volume>9</volume><fpage>p. 241</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00241</pub-id><pub-id pub-id-type="other">2-s2.0-85067563927</pub-id><pub-id pub-id-type="pmcid">PMC6481273</pub-id><pub-id pub-id-type="pmid">31058074</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pham</surname><given-names>T. N.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Min</surname><given-names>J. J.</given-names></name><etal/></person-group><article-title>Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of toll-like receptor agonist</article-title><source><italic toggle="yes">Experimental &amp; Molecular Medicine</italic></source><year>2010</year><volume>42</volume><issue>6</issue><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.3858/emm.2010.42.6.042</pub-id><pub-id pub-id-type="other">2-s2.0-77954708184</pub-id><pub-id pub-id-type="pmid">20386085</pub-id><pub-id pub-id-type="pmcid">PMC2892594</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freen-van Heeren</surname><given-names>J. J.</given-names></name></person-group><article-title>Toll-like receptor-2/7-mediated T cell activation: an innate potential to augment CD8(+) T cell cytokine production</article-title><source><italic toggle="yes">Scandinavian Journal of Immunology</italic></source><year>2021</year><volume>93</volume><pub-id pub-id-type="doi">10.1111/sji.13019</pub-id><pub-id pub-id-type="pmid">33377182</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Critical role of toll-like receptor signaling in NK cell activation</article-title><source><italic toggle="yes">Chinese Science Bulletin</italic></source><year>2012</year><volume>57</volume><issue>24</issue><fpage>3192</fpage><lpage>3202</lpage><pub-id pub-id-type="doi">10.1007/s11434-012-5257-1</pub-id><pub-id pub-id-type="other">2-s2.0-84865833149</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreibelt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sliepen</surname><given-names>K. H. E. W. J.</given-names></name><etal/></person-group><article-title>Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2010</year><volume>59</volume><issue>10</issue><fpage>1573</fpage><lpage>1582</lpage><pub-id pub-id-type="doi">10.1007/s00262-010-0833-1</pub-id><pub-id pub-id-type="other">2-s2.0-77955557963</pub-id><pub-id pub-id-type="pmid">20204387</pub-id><pub-id pub-id-type="pmcid">PMC11029854</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>C. M.</given-names></name></person-group><article-title>Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy</article-title><source><italic toggle="yes">Current Opinion in Biotechnology</italic></source><year>2019</year><volume>60</volume><fpage>138</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2019.01.010</pub-id><pub-id pub-id-type="other">2-s2.0-85062214541</pub-id><pub-id pub-id-type="pmid">30831487</pub-id><pub-id pub-id-type="pmcid">PMC6717700</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;nez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pitter</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>Trial Watch: toll-like receptor agonists in cancer immunotherapy</article-title><source><italic toggle="yes">Oncoimmunology</italic></source><year>2018</year><volume>7</volume><issue>12, article e1526250</issue><pub-id pub-id-type="doi">10.1080/2162402X.2018.1526250</pub-id><pub-id pub-id-type="other">2-s2.0-85058033462</pub-id><pub-id pub-id-type="pmid">30524908</pub-id><pub-id pub-id-type="pmcid">PMC6279325</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blazquez</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Meseck</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma</article-title><source><italic toggle="yes">Cancer Immunology Research</italic></source><year>2020</year><volume>8</volume><issue>1</issue><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-19-0545</pub-id><pub-id pub-id-type="pmid">31699709</pub-id><pub-id pub-id-type="pmcid">PMC6946846</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slingluff</surname><given-names>C. L.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Petroni</surname><given-names>G. R.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>W. C.</given-names></name><etal/></person-group><article-title>A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites</article-title><source><italic toggle="yes">Cancer Immunology, Immunotherapy</italic></source><year>2016</year><volume>65</volume><issue>1</issue><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s00262-015-1770-9</pub-id><pub-id pub-id-type="other">2-s2.0-84953369771</pub-id><pub-id pub-id-type="pmid">26581199</pub-id><pub-id pub-id-type="pmcid">PMC5010424</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shayan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kansy</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>S. P.</given-names></name><etal/></person-group><article-title>Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2018</year><volume>24</volume><issue>1</issue><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0357</pub-id><pub-id pub-id-type="other">2-s2.0-85040046312</pub-id><pub-id pub-id-type="pmid">29061643</pub-id><pub-id pub-id-type="pmcid">PMC5754237</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>L. Q. M.</given-names></name><name name-style="western"><surname>Morishima</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eaton</surname><given-names>K. D.</given-names></name><etal/></person-group><article-title>Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN</article-title><source><italic toggle="yes">Clinical Cancer Research</italic></source><year>2017</year><volume>23</volume><issue>10</issue><fpage>2442</fpage><lpage>2450</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-1934</pub-id><pub-id pub-id-type="other">2-s2.0-85020471606</pub-id><pub-id pub-id-type="pmid">27810904</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrotra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Britten</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer</article-title><source><italic toggle="yes">Journal of Hematology &amp; Oncology</italic></source><year>2017</year><volume>10</volume><issue>1</issue><fpage>p. 82</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0459-2</pub-id><pub-id pub-id-type="other">2-s2.0-85018520257</pub-id><pub-id pub-id-type="pmid">28388966</pub-id><pub-id pub-id-type="pmcid">PMC5384142</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belani</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Modi</surname><given-names>R. I.</given-names></name><name name-style="western"><surname>Khamar</surname><given-names>B. M.</given-names></name></person-group><article-title>A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer</article-title><source><italic toggle="yes">Annals of Oncology</italic></source><year>2017</year><volume>28</volume><issue>2</issue><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw608</pub-id><pub-id pub-id-type="other">2-s2.0-85019618797</pub-id><pub-id pub-id-type="pmid">27831503</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>L. G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Reichow</surname><given-names>J. L.</given-names></name><etal/></person-group><article-title>Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial</article-title><source><italic toggle="yes">JAMA Oncology</italic></source><year>2017</year><volume>3</volume><issue>7</issue><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.6007</pub-id><pub-id pub-id-type="other">2-s2.0-85021648715</pub-id><pub-id pub-id-type="pmid">28114604</pub-id><pub-id pub-id-type="pmcid">PMC5824239</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ronsley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kariminia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: results of the TACL T2009-008 phase I study</article-title><source><italic toggle="yes">Pediatric Hematology and Oncology</italic></source><year>2019</year><volume>36</volume><issue>8</issue><fpage>468</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1080/08880018.2019.1667461</pub-id><pub-id pub-id-type="other">2-s2.0-85073998057</pub-id><pub-id pub-id-type="pmid">31530240</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Targeting TLRs expressed on the immune cells in the tumor microenvironment with TLR agonists. Examples of TLR agonists are shown at the top. TLRs which are expressed in human cell surface or intracellular compartments are shown in the middle. The expression of each TLR on different immune cell types is indicated by color-coded lines. Some reported low-level expressions of TLRs with unknown functional status are ignored in this figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2021-9912188.001.jpg"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>TLR-based strategies for improvement of CAR T cells. (a) Schematic presentation of wild-type T cell proteins from which signaling domains are derived to construct chimeric synthetic receptors. (b) Traditional second-generation CAR containing an scFV domain for antigen recognition on the extracellular portion and CD3<italic toggle="yes">&#950;</italic> and costimulatory signaling domains on the cytosolic side (CD28 domain is shown here as an example). (c) A third-generation CAR with a TIR signaling domain derived from TLRs. (d) A CD40-MyD88 fusion protein tethered to a first-generation CAR through an inefficient 2A linker. (e) The CD40-MyD88 fusion is linked to a rimiducid-binding domain from an FKBP protein to form a pharmacological switch that can transmit a costimulatory signal by dimerization upon rimiducid treatment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2021-9912188.002.jpg"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>A summary of TLR agonists with their corresponding TLR targets.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Target TLR</th><th align="center" rowspan="1" colspan="1">Agonist</th><th align="center" rowspan="1" colspan="1">Molecule type</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">TLR2</td><td align="center" rowspan="1" colspan="1">Pam3Cys</td><td align="center" rowspan="1" colspan="1">Lipoproteins</td><td align="center" rowspan="1" colspan="1">[<xref rid="B94" ref-type="bibr">94</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">SMP-105</td><td align="center" rowspan="1" colspan="1">Cell wall skeleton components</td><td align="center" rowspan="1" colspan="1">[<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">CBLB612</td><td align="center" rowspan="1" colspan="1">Lipopeptide</td><td align="center" rowspan="1" colspan="1">[<xref rid="B97" ref-type="bibr">97</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">TLR3</td><td align="center" rowspan="1" colspan="1">Poly I:C</td><td align="center" rowspan="5" colspan="1">Synthetic dsRNA</td><td align="center" rowspan="1" colspan="1">[<xref rid="B98" ref-type="bibr">98</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Poly-ICLC</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Poly-IC12U</td><td align="center" rowspan="1" colspan="1">[<xref rid="B100" ref-type="bibr">100</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">IPH 3102</td><td align="center" rowspan="1" colspan="1">[<xref rid="B101" ref-type="bibr">101</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">ARNAX</td><td align="center" rowspan="1" colspan="1">[<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B103" ref-type="bibr">103</xref>]</td></tr><tr><td align="left" rowspan="4" colspan="1">TLR4</td><td align="center" rowspan="1" colspan="1">MPLA</td><td align="center" rowspan="1" colspan="1">Lipid</td><td align="center" rowspan="1" colspan="1">[<xref rid="B104" ref-type="bibr">104</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">GLA-SE</td><td align="center" rowspan="1" colspan="1">Lipid</td><td align="center" rowspan="1" colspan="1">[<xref rid="B105" ref-type="bibr">105</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">AS04</td><td align="center" rowspan="1" colspan="1">MPL and aluminum hydroxide</td><td align="center" rowspan="1" colspan="1">[<xref rid="B106" ref-type="bibr">106</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">OK-432</td><td align="center" rowspan="1" colspan="1">Low virulence <italic toggle="yes">Streptococcus pyogenes</italic> strain</td><td align="center" rowspan="1" colspan="1">[<xref rid="B107" ref-type="bibr">107</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">TLR5</td><td align="center" rowspan="1" colspan="1">CBLB502</td><td align="center" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">[<xref rid="B61" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">M-VM3</td><td align="center" rowspan="1" colspan="1">Adenoviral vector</td><td align="center" rowspan="1" colspan="1">[<xref rid="B74" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR7</td><td align="center" rowspan="1" colspan="1">Bistriazolyl</td><td align="center" rowspan="1" colspan="1">Small molecule</td><td align="center" rowspan="1" colspan="1">[<xref rid="B108" ref-type="bibr">108</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR8</td><td align="center" rowspan="1" colspan="1">VTX1463</td><td align="center" rowspan="1" colspan="1">Small molecule</td><td align="center" rowspan="1" colspan="1">[<xref rid="B109" ref-type="bibr">109</xref>]</td></tr><tr><td align="left" rowspan="8" colspan="1">TLR9</td><td align="center" rowspan="1" colspan="1">MGN1703</td><td align="center" rowspan="1" colspan="1">Polynucleotide</td><td align="center" rowspan="1" colspan="1">[<xref rid="B61" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">CpG-7909</td><td align="center" rowspan="7" colspan="1">Oligonucleotide</td><td align="center" rowspan="1" colspan="1">[<xref rid="B110" ref-type="bibr">110</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">IMO2055</td><td align="center" rowspan="1" colspan="1">[<xref rid="B111" ref-type="bibr">111</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">dSLIM</td><td align="center" rowspan="1" colspan="1">[<xref rid="B61" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">SD-101</td><td align="center" rowspan="1" colspan="1">[<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">KSK-CpG</td><td align="center" rowspan="1" colspan="1">[<xref rid="B88" ref-type="bibr">88</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">ODN M362</td><td align="center" rowspan="1" colspan="1">[<xref rid="B114" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">CpG-1826</td><td align="center" rowspan="1" colspan="1">[<xref rid="B115" ref-type="bibr">115</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical studies on the application of TLR agonists for cancer treatment published since 2016.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Target TLR</th><th align="center" rowspan="1" colspan="1">TLR agonist</th><th align="center" rowspan="1" colspan="1">Companion treatment</th><th align="center" rowspan="1" colspan="1">Conditions</th><th align="center" rowspan="1" colspan="1">Phase</th><th align="center" rowspan="1" colspan="1">Results</th><th align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TLR2</td><td align="center" rowspan="1" colspan="1">CADI-05</td><td align="center" rowspan="1" colspan="1">Chemotherapy (cisplatin-paclitaxel)</td><td align="center" rowspan="1" colspan="1">Non-small-cell lung cancer</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">No survival benefit was observed with the addition of CADI-05 to chemotherapy.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" rowspan="2" colspan="1">TLR3</td><td align="center" rowspan="2" colspan="1">Poly-ICLC</td><td align="center" rowspan="1" colspan="1">NY-ESO-1 peptide vaccine</td><td align="center" rowspan="1" colspan="1">Melanoma</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Enhanced specific CD8+ T cell response.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B138" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Peptide-pulsed DCs</td><td align="center" rowspan="1" colspan="1">Pancreatic cancer</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">The treatment was safe and induced a measurable tumor-specific T cell population.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR3, TLR4</td><td align="center" rowspan="1" colspan="1">Poly-ICLC, LPS</td><td align="center" rowspan="1" colspan="1">Multipeptide vaccine and incomplete Freund's adjuvant</td><td align="center" rowspan="1" colspan="1">Melanoma</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Combinations of poly-ICLC or LPS with peptide vaccine and incomplete Freund's adjuvant are safe and induce T cell response.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B99" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR4 TLR9</td><td align="center" rowspan="1" colspan="1">AS15</td><td align="center" rowspan="1" colspan="1">Recombinant MAGE-A3 vaccine</td><td align="center" rowspan="1" colspan="1">Melanoma</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">The treatment was tolerated and produced durable Ab responses.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B139" ref-type="bibr">139</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR7</td><td align="center" rowspan="1" colspan="1">Imiquimod</td><td align="center" rowspan="1" colspan="1">Chemotherapy (paclitaxel)</td><td align="center" rowspan="1" colspan="1">Breast cancer cutaneous metastases</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">The combination was effective in inducing disease regression, but responses were short-lived.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B144" ref-type="bibr">144</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR8</td><td align="center" rowspan="1" colspan="1">Motolimod</td><td align="center" rowspan="1" colspan="1">Anti-EGFR (cetuximab)</td><td align="center" rowspan="1" colspan="1">Head and neck squamous cell carcinoma</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">The addition of TLR agonist enhanced the cellular antitumor immune response.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR9</td><td align="center" rowspan="1" colspan="1">GNKG168</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Minimal residual disease positive acute leukemia</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Immunologic changes were observed.</td><td align="center" rowspan="1" colspan="1">[<xref rid="B145" ref-type="bibr">145</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>A summary of recent ongoing clinical trials on TLR agonists started after 2019.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Target TLR</th><th align="center" rowspan="1" colspan="1">TLR agonist</th><th align="center" rowspan="1" colspan="1">Companion treatment</th><th align="center" rowspan="1" colspan="1">Conditions<sup>&#8727;</sup></th><th align="center" rowspan="1" colspan="1">Phase</th><th align="center" rowspan="1" colspan="1">Status</th><th align="center" rowspan="1" colspan="1">NCT number</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TLR2/4</td><td align="center" rowspan="1" colspan="1">BCG, PPD, Typhim Vi</td><td align="center" rowspan="1" colspan="1">Chemotherapy, radiofrequency ablation</td><td align="center" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04062721">NCT04062721</ext-link>
</td></tr><tr><td align="left" rowspan="2" colspan="1">TLR3</td><td align="center" rowspan="1" colspan="1">Poly-ICLC</td><td align="center" rowspan="1" colspan="1">Peptide vaccine, anti-CD40</td><td align="center" rowspan="1" colspan="1">Melanoma</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04364230">NCT04364230</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Rintatolimod</td><td align="center" rowspan="1" colspan="1">Anti-PD-1, chemotherapy</td><td align="center" rowspan="1" colspan="1">Ovarian cancer recurrent</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03734692">NCT03734692</ext-link>
</td></tr><tr><td align="left" rowspan="2" colspan="1">TLR4</td><td align="center" rowspan="2" colspan="1">GLA-SE</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">Lymphoma, T cell, cutaneous</td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">Withdrawn</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03742804">NCT03742804</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Anti-CTLA-4, anti-PD-1, chemotherapy</td><td align="center" rowspan="1" colspan="1">Colorectal cancer metastatic</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Withdrawn</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03982121">NCT03982121</ext-link>
</td></tr><tr><td align="left" rowspan="4" colspan="1">TLR7</td><td align="center" rowspan="1" colspan="1">BNT411</td><td align="center" rowspan="1" colspan="1">Anti-PDL-1, chemotherapy</td><td align="center" rowspan="1" colspan="1">Solid tumor, lung cancer</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04101357">NCT04101357</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Imiquimod</td><td align="center" rowspan="1" colspan="1">Anti-PD-1, focused ultrasound ablation</td><td align="center" rowspan="1" colspan="1">Multiple solid tumors</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04116320">NCT04116320</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">RO7119929</td><td align="center" rowspan="1" colspan="1">Anti-IL-6 receptor</td><td align="center" rowspan="1" colspan="1">Biliary tract and liver cancer</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04338685">NCT04338685</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">SHR2150</td><td align="center" rowspan="1" colspan="1">Chemotherapy, anti-PD-1, anti-CD47</td><td align="center" rowspan="1" colspan="1">Solid tumor</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04588324">NCT04588324</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR7/8</td><td align="center" rowspan="1" colspan="1">TransCon</td><td align="center" rowspan="1" colspan="1">Anti-PD-1</td><td align="center" rowspan="1" colspan="1">Solid tumors</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04799054">NCT04799054</ext-link>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR8</td><td align="center" rowspan="1" colspan="1">Motolimod</td><td align="center" rowspan="1" colspan="1">Anti-PD-1</td><td align="center" rowspan="1" colspan="1">Carcinoma, squamous cell</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03906526">NCT03906526</ext-link>
</td></tr><tr><td align="left" rowspan="6" colspan="1">TLR9</td><td align="center" rowspan="3" colspan="1">CMP-001</td><td align="center" rowspan="1" colspan="1">Anti-OX40</td><td align="center" rowspan="1" colspan="1">Pancreatic cancer, unresectable solid neoplasm</td><td align="center" rowspan="1" colspan="1">I/II</td><td align="center" rowspan="1" colspan="1">Not yet recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04387071">NCT04387071</ext-link>
</td></tr><tr><td align="center" rowspan="2" colspan="1">Anti-PD-1</td><td align="center" rowspan="2" colspan="1">Melanoma</td><td align="center" rowspan="2" colspan="1">II</td><td align="center" rowspan="2" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04708418">NCT04708418</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04401995">NCT04401995</ext-link>
</td></tr><tr><td align="center" rowspan="2" colspan="1">SD-101</td><td align="center" rowspan="1" colspan="1">Radiation therapy, anti-PD-1</td><td align="center" rowspan="1" colspan="1">Pancreatic cancer</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04050085">NCT04050085</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Anti-OX40</td><td align="center" rowspan="1" colspan="1">Malignant solid neoplasm</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03831295">NCT03831295</ext-link>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Tilsotolimod</td><td align="center" rowspan="1" colspan="1">Anti-CTLA-4, anti-PD-1</td><td align="center" rowspan="1" colspan="1">Advanced cancer</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">Recruiting</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04270864">NCT04270864</ext-link>
</td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#8727;</sup>Indicated conditions are summarized in this table. Complete information is available via the provided ClinicalTrials.gov identifier (NCT number).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>